Heterocyclic compounds and their preparation and use

ABSTRACT

The present invention relates to therapeutically active azacyclic or azabicyclic compounds, a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

This application is a division of application Ser. No. 08/443,673, filedon Jun. 1, 1995, now abandoned which is a continuation in part ofapplication Ser. No. 08/327,766 filed Oct. 24, 1995, still pending.

FIELD OF THE INVENTION

The present invention relates to therapeutically active azacyclic orazabicyclic compounds, a method of preparing the same and tocompositions for pharmaceutical or veterinary use comprising thecompounds with a carrier. The novel compounds are useful as stimulantsof the cognitive function of the forebrain and hippocampus of mammalsand especially in the treatment of Alzheimer's disease.

BACKGROUND OF THE INVENTION

Due to the generally improved health situation in the western world,elderly-related diseases are much more common now than in the past andare likely to be even more common in the future.

One of the elderly-related symptoms is a reduction of the cognitivefunctions. This symptom is especially pronounced in thepathophysiological disease known as Alzheimer's disease. This disease iscombined with, and also most likely caused by, an up to 90% degenerationof the muscarinic cholinergic neurons in nucleus basalis, which is partof substantia innominata. These neurons project to the prefrontal cortexand hippocampus and have a general stimulatory effect on the cognitivefunctions of the forebrain as well as of hippocampus, namely learning,association, consolidation, and recognition.

It is a characteristic of Alzheimer's disease that although thecholinergic neurons degenerate, the postsynaptic muscarinic receptors inthe forebrain and hippocampus still exist. Therefore, muscariniccholinergic agonists are useful in the treatment of Alzheimer's disease,in halting its progression, and in improving the cognitive functions ofelderly people.

The compounds of this invention are also useful analgesic agents andtherefore are useful in the treatment of severely painful conditions.

Furthermore, the compounds of this invention are useful in the treatmentof glaucoma, psychosis, mania, bipolar disorder, schizophrenia orschizophreniform conditions, depression, sleeping disorders, epilepsy,cerebral ischemia, and gastrointestinal motility disorders.

SUMMARY OF THE INVENTION

It is an object of the invention to provide new muscarinic cholinergiccompounds.

The novel compounds of the invention are heterocyclic compounds havingthe formula I' ##STR1## wherein W is oxygen or sulphur;

R is hydrogen, amino, halogen, NHR⁶, NR⁶ R⁷, R⁴, --OR⁴, --SR⁴, --SOR⁴,--SO₂ R⁴, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀-cycloalkyl and --Z--C₄₋₁₂ -(cycloalkylalkyl) wherein R⁴ is C₁₋₁₅-alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl, each of which is optionallysubstituted with one or more halogen(s), --CF₃, --CN, Y, phenyl orphenoxy wherein phenyl or phenoxy is optionally substituted withhalogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃, --CF₃, --CONH₂ or--CSNH₂ ; or

R is phenyl or benzyloxycarbonyl, each of which is optionallysubstituted with halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃,--CF₃, --CONH₂ or --CSNH₂ ; or

R is --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y, --SR⁵ ZY, --O--R⁵ --Z--R⁴ or --S--R⁵--Z--R⁴ wherein Z is oxygen or sulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, C₂₋₁₅ -alkynyl, and Y is a 5 or 6 membered heterocyclic group;and

G is selected from one of the following azacyclic or azabicyclic ringsystems: ##STR2## or G can optionally be substituted C₃ -C₈ cycloalkylor optionally substituted C₁₋₆ -alkyl wherein the substitution is --NR⁶R⁷ ;

R⁶ and R⁷ independently are hydrogen, C₁₋₆ -alkyl; or

R⁶ and R⁷ together with the nitrogen atom optionally form a 4- to6-member ring;

R¹ and R² independently are hydrogen, C₁₋₁₅ -alkyl, C₂₋₅ -alkenyl, C₂₋₅-alkynyl, C₁₋₁₀ -alkoxy, C₁₋₅ -alkyl substituted with --OH, --COR^(6'),CH₂ --OH, halogen, --NH₂, carboxy, or phenyl;

R³ is hydrogen, C₁₋₅ -alkyl, C₂₋₅ -alkenyl or C₂₋₅ -alkynyl;

n is 0, 1 or 2;

m is 0, 1 or 2;

p is 0, 1 or 2;

q is 1 or 2;

r is 0, 1 or 2;

. . . . . . . is a single or double bond;

provided that when W is oxygen and G is alkyl, R is selected from thegroup consisting of hydrogen, amino, NHR⁶, NR⁶ R⁷, R⁴, --OR⁴, --SR⁴,--SOR⁴, --SO₂ R⁴, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl),--Z--C₃₋₁₀ -cycloalkyl and --Z--C₄₋₁₂ -(cycloalkylalkyl), phenyl orbenzyloxycarbonyl, each of which is optionally substituted with halogen,--CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃, --CF₃, --CONH₂ or --CSNH₂ ; or

R is --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y, --SR⁵ ZY, --O--R⁵ --Z--R⁴ or --S--R⁵--Z--R⁴ wherein Z is oxygen or sulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, C₂₋₁₅ -alkynyl; or

a pharmaceutically acceptable salt or solvate thereof.

The invention also relates to methods of preparing the above mentionedcompounds, comprising reacting a compound of formula III ##STR3##wherein P is R⁹ SO₂ or halogen; R⁹ is C₁₋₈ alkyl or aryl; and R has themeaning defined above; with G--(CH₂)_(r) --W--h⁺ wherein h⁺ is analkoxide metal, G, W and r have the meanings defined above.

A further aspect of this invention provides novel compounds of formulaIV and a process for preparing compounds of the formula IV ##STR4##comprising reacting a compound of the formula III wherein P is Cl##STR5## with R⁸ N[(R¹⁰ R¹¹ R¹² Si)(R¹³ R¹⁴ R¹⁵ Si) wherein R has themeaning defined supra. R⁸ is Li, Na, or K; Si means silyl; R¹⁰,R¹¹, R¹²,R¹³, R¹⁴ and R^(15') are independently selected from the groupconsisting of (C₁ -C₆)-alkyl, aryl, and aryl(C₁ -C₃)alkyl; R¹⁵ and R¹⁶are independently selected from the group consisting of hydrogen, R¹⁰R¹¹ R¹² Si, and R¹³ R¹⁴ R^(15') Si.

R is selected from the group consisting of hydrogen, amino, halogen,NHR⁶, NR⁶ R⁷, R⁴, --OR⁴, --SR⁴, --SOR⁴, --SO₂ R⁴, C₃₋₁₀ -cycloalkyl,C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀ -cycloalkyl and --Z--C₄₋₁₂-(cycloalkylalkyl) wherein R⁴ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅-alkynyl, each of which is optionally substituted with one or morehalogen(s), --CF₃, --CN, Y, phenyl or phenoxy wherein phenyl or phenoxyis optionally substituted with halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy,--OCF₃, --CF₃, --CONH₂ or --CSNH₂ ; or

R is phenyl or benzyloxycarbonyl, each of which is optionallysubstituted with halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃,--CF₃, --CONH₂ or --CSNH₂ ; or

R is --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y, --SR⁵ ZY, --O--R⁵ --Z--R⁴ or --S--R⁵--Z-R⁴ wherein Z is oxygen or sulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, C₂₋₁₅ -alkynyl, and Y is a 5 or 6 membered heterocyclic group;

provided that when R is hydrogen, amine, or halogen, R¹⁶ shall beselected from the group consisting of (R¹⁰ R¹¹ R¹² Si) and (R¹³ R¹⁴R^(15') Si).

Finally, compounds of Formula V are provided by the present invention;##STR6## wherein w' is selected from the group consisting of O, S andSO₂ ; R¹⁷ is selected from the group consisting of C₁ -C₆ alkyl, aryl,R¹⁹ substituted alkyl, and R¹⁹ substituted aryl;

R¹⁹ is selected from the group consisting of straight or branched C₁ -C₆alkyl, straight or branched C₂ -C₆ alkenyl, halogen, halogen(C₁-C₆)alkyl, halogen(C₂ -C₆)alkenyl, COR²⁰, C₂ -C₁₀ alkanoyl, CO₂ R²⁰, (C₁-C₆ alkyl)₂ amino, NO₂, SR²⁰, OR²⁰, C₃ -C₈ cycloalkyl, C₃ -C₈cycloalkyl-(C₁ -C₃)alkyl, C₅ -C₈ cycloalkenyl, substituted C₅ -C₈cycloalkenyl, C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl, and C₇ -C₁₆ arylalkyl;R²⁰ is independently selected from the group consisting of hydrogen, andC₁ -C₄ alkyl; wherein the R¹⁹ substituent may be attached at anyavailable carbon atom;

R¹⁸ is R⁴ SO₂, Cl, Br or I;

provided that when W' is O; and R is C₁ -C₅ alkyl or aryl; then R¹⁸ isselected from R⁴ SO₂, Br and I; or

a pharmaceutically acceptable salt or solvate thereof.

It is to be understood that the invention extends to each of thestereoisomeric forms of the compounds of the present invention as wellas the pure diastereomeric, pure enatiomeric, and racemic forms of thecompounds of this invention.

The invention further relates to a process for preparing theintermediates of Formulas II ##STR7## or III supra., comprising reacting(CN)₂ with R⁴ --S--H or G(CH₂)_(r) --W--H, wherein P, R⁴, G, r, and Whave the meaning defined above and which formed compound is subsequentlyreacted with S₂ Cl₂ to form a compound of formula II or III.

As used herein the term "treating" includes prophylaxis of a physicalandr mental condition or amelioration or elimination of the developedphysical and/or mental condition once it has been established oralleviation of the characteristic symptoms of such condition.

As used herein with reference to the G substituent, the --(CH₂)_(r)--W-thiadiazole moiety can be attached at any carbon atom of theazacyclic or azabicyclic ring. Further, R¹ and R² of the G substituentmay be present at any position, including the point of attachment of the--(CH₂)_(r) --W-thiadiazole moiety.

As used herein with reference to the G substituent, the phrase "R⁶ andR⁷ together with the nitrogen atom optionally form a 4- to 6-memberring" means that R⁶ and R⁷ are each independently hydrogen, C₁ -C₆ alkylwherein the R⁶ and R⁷ groups may optionally join to form a 4- to6-member ring including the nitrogen. For example, optionally joinedgroups include, but are not limited to: ##STR8##

As used herein the phrase "interacting with a muscarinic cholinergicreceptor" shall include compounds which block muscarinic cholinergicreceptors or modulate such receptors. The phrase shall include theeffect observed when compounds act as agonists, partial agonists and/orantagonists at a muscarinic cholinergic receptor.

As used herein, the term "alkoxide metal" means a metal suitable foralkoxide formation. Such alkoxide metals include, but are not limitedto, Li⁺, K⁺, Na⁺, Cs⁺, and Ca⁺⁺. Especially preferred alkoxide metalsinclude Li⁺, K⁺, and Na⁺.

As used herein, the term "halogen" means Cl, Br, F, and I. Especiallypreferred halogens include Cl, Br, and I.

As used herein the phrase "one or more selected from" shall morepreferredly refer to from 1-3 substituents. The term shall furtherpreferredly refer to from 1-2 substituents.

The terms "C₁ -C_(n') alkyl" wherein n' can be from 2 through 15, asused herein, represent a branched or linear alkyl group having from oneto the specified number of carbon atoms. Typical C₁ -C₆ alkyl groupsinclude, but are not limited to, methyl, ethyl, n-propyl, iso-propyl,butyl, iso-butyl, sec-butyl, tert-butyl, pentyl, hexyl and the like.

The terms "C₂ -C_(n'), alkenyl" wherein n' can be from 3 through 10, asused herein, represents an olefinically unsaturated branched or lineargroup having from 2 to the specified number of carbon atoms and at leastone double bond. Examples of such groups include, but are not limitedto, 1-propenyl, 2-propenyl (--CH₂ --CH═CH₂), 1,3-butadienyl,(--CH═CHCH═CH₂), 1-butenyl (--CH═CHCH₂ CH₃), hexenyl, pentenyl, and thelike.

The term "C₂ -C₅ alkynyl" refers to an unsaturated branched or lineargroup having from 2 to 5 carbon atoms and at least one triple bond.Examples of such groups include, but are not limited to, 1-propynyl,2-propynyl, 1-butynyl, 2-butynyl, 1-pentynyl, and the like.

The terms "halogen(C₁ -C₆)alkyl" and "halogen(C₂ -C₆)alkenyl" refer toalkyl or alkenyl substituents having one or more independently selectedhalogen atoms attached at one or more available carbon atoms. Theseterms include, but are not limited to, chloromethyl, 1-bromoethyl,2-bromoethyl, 1,1,1-trifluoroethyl, 1,1,2-trifluoroethyl,1,2,2-trifluoroethyl, 2,2,2-trifluoroethyl, trifluoromethyl,trifluoroethylenyl, 3-bromopropyl, 3-bromo-1-propenyl, 2-bromopropyl,2-bromo-1-propenyl, 3-chlorobutyl, 3-chloro-2-butenyl,2,3-dichlorobutyl, 1-chloroethylenyl, 2-chloroethylenyl,5-fluoro-3-pentenyl, 3-chloro-2-bromo-5-hexenyl, 3-chloro-2-bromobutyl,trichloromethyl, 1,1-dichloroethyl, 1,2-dichloroethyl,2,2-dichloroethyl, 1,4-dichlorobutyl, 3-bromopentyl, 1,3-dichlorobutyl,1,1-dichloropropyl, and the like.

The term "C₂ -C₁₀ alkanoyl" represents a group of the formula C(O)(C₁-C₉) alkyl. Typical C₂ -C₁₀ alkanoyl groups include acetyl, propanoyl,butanoyl, and the like.

The term "(C₁ -C₆ alkyl) amino" refers to a monoalkylamino group.Examples of such groups are methylamino, ethylamino, iso-propylamino,n-propylamino, (n-propyl)amino, (iso-propyl)amino, n-propylamino,t-butylamino, and the like.

The term "C₃ -C_(n) cycloalkyl" wherein n=4-8, represents cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

The term "substituted(C₅ -C_(n')) cycloalkyl" refers to a cycloalkylgroup as described supra wherein the cycloalkyl group may be substitutedwith from one to four substituents independently selected from the groupconsisting of hydrogen, C₁ -C₆ alkyl, NO₂, halogen, halogen(C₁-C₆)alkyl, halogen(C₂ -C₆)alkenyl, C₂ -C₆ alkenyl, CO₂ R²⁰, (C₁ -C₆alkyl) amino, --SR²⁰, and OR²⁰ ; wherein R²⁰ is selected from the groupconsisting of C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl.

The term "C₃ -C₈ cycloalkyl-(C₁ -C₃)alkyl" represents an alkyl groupsubstituted at a terminal carbon with a C₃ -C₈ cycloalkyl group. Typicalcycloalkylalkyl groups include cyclohexylethyl, cyclohexylmethyl,3-cyclopentylpropyl, and the like.

The term "C₅ -C₈ cycloalkenyl" represents an olefinically unsaturatedring having five to eight carbon atoms, Such groups include, but are notlimited to, cyclohexyl-1,3-dienyl, cyclohexenyl, cyclopentenyl,cycloheptenyl, cyclooctenyl, cyclohexyl-1,4-dienyl,cycloheptyl-1,4-dienyl, cyclooctyl-1,3,5-trienyl and the like.

The term "substituted (C₅ -C₈) cycloalkenyl" refers to a cycloalkenylgroup as described supra. wherein the cycloalkenyl group may besubstituted with from one to four substituents independently selectedfrom the group consisting of hydrogen, C₁ -C₆ alkyl, NO₂, halogen,halogen(C₁ -C₆)alkyl, halogen(C₂ -C₆)alkenyl, C₂ -C₆ alkenyl, COR²⁰, C₂-C₁₀ alkanoyl, C₇ -C₁₆ arylalkyl, CO₂ R²⁰, (C₁ -C₆ alkyl) amino, --SR²⁰,and --OR²⁰ ; wherein R²⁰ is selected from the group consisting of C₁₋₁₅-alkyl, C₂₋₁₅ -alkenyl, and C₂₋₁₅ -alkynyl.

The term "C₅ -C₈ cycloalkenyl-(C₁ -C₃)alkyl" represents a C₁ -C₃ alkylgroup substituted at a terminal carbon with a C₅ -C₈ cycloalkenyl group.

As used herein, the phrase "5 or 6 membered heterocyclic group" means agroup containing from one to four N, O or S atom(s) or a combinationthereof, which heterocyclic group is optionally substituted at carbon ornitrogen atom(s) with C₁₋₆ -alkyl, --CF₃, phenyl, benzyl or thienyl, ora carbon atom in the heterocyclic group together with an oxygen atomform a carbonyl group, or which heterocyclic group is optionally fusedwith a phenyl group. The phrase "5 or 6 membered heterocyclic group"includes, but is not limited to, 5-membered heterocycles having onehetero atom (e.g. thiophenes, pyrroles, furans); 5-membered heterocycleshaving two heteroatoms in 1,2 or 1,3 positions (e.g. oxazoles,pyrazoles, imidazoles, thiazoles, purines); 5-membered heterocycleshaving three heteroatoms (e.g. triazoles, thiadiazoles); 5-memberedheterocycles having 3-heteroatoms; 6-membered heterocycles with oneheteroatom (e.g. pyridine, quinoline, isoquinoline, phenanthrine,5,6-cycloheptenopyridine); 6-membered heterocycles with two heteroatoms(e.g. pyridazines, cinnolines, phthalazines, pyrazines, pyrimidines,quinazolines); 6-membered heterocycles with three heteroatoms (e.g.1,3,5-triazine); and 6-member heterocycles with four heteroatoms.Particularly preferred are thiophenes, pyridines, and furans.

As used herein the term "carboxy" refers to a substituent having thecommon meaning understood by the skilled artisan, wherein the point-ofattachment may be through the carbon or oxygen atom of the group.

As used herein the term "aryl" means an organic radical derived from anaromatic hydrocarbon by the removal of one atom; e.g., phenyl ornaphthyl. Most preferably, aryl refers to C₆ -C₁₀ aryl, wherein the arylring system, including any alkyl substitutions, comprises from 6 to 10carbon atoms; e.g., phenyl, 3,3-dimethylphenyl, naphthyl, and the like.The aryl radical may be substituted by one or two C₁ -C₆ straight orbranched alkyl. The term "aryl(C₁ -C₃)alkyl" refers to any aryl groupwhich is attached to the parent moiety via the alkyl group.

As used herein the term "phosphorous(III) compound" has the art acceptedmeaning of the term. For example, the term includes, but is in no waylimited to, triphenylphosphine, tri(p-toluyl) phosphine, tributylphosphine, tri(p-dimethylaminiophenyl) phosphine, triethyl phosphine,and trimethyl phosphine. The artisan can choose other appropriatephosphorous(III) compounds using methods and literature references whichare commonly available to the chemist artisan.

As used herein the term "diester of azodicarboxylate" has the artaccepted meaning of the term. For example, the term includes, but is inno way limited to diethylazodicarboxylate, dimethylazodicarboxylate,diisopropylazodicarboxylate, and di-tertbutylazodicarboxylate. Theskilled chemist can determine other appropriate diesters ofazodicarboxylate using methods and literature readily available to thechemist artisan.

Examples of pharmaceutically acceptable salts include inorganic andorganic acid addition salts such as hydrochloride, hydrobromide,sulphate, phosphate, acetate, fumarate, maleate, citrate, lactate,tartrate, oxalate, or similar pharmaceutically-acceptable inorganic ororganic acid addition salts, and include the pharmaceutically acceptablesalts listed in Journal of pharmaceutical Science, 66, 2 (1977) whichare known to the skilled artisan. The compounds of this invention mayform solvates with standard low molecular weight solvents using methodsknown to the skilled artisan.

The compounds of this invention can be prepared using the chemicalprocesses illustrated in Scheme I. The starting materials for theillustrated process are commercially available or may be prepared usingmethods known to the skilled artisan. ##STR9##

As used in Scheme I, R, h⁺, and G are as defined supra. As used inScheme I, the term "Hal" refers to Cl, Br, and R⁹ SO₂. Preferredoxidizing agents for the process of Scheme I include oxone and sodiumperiodate. Oxone is an especially preferred oxidizing agent for theprocess of Scheme I. Compounds of Formula 3, as illustrated in Scheme Iwherein the OR group is replaced by an R⁴ group, can be prepared usingmethods well known in the art. See for example, U.S. Pat. No. 5,043,345.

Further, compounds of Formula I may be prepared using the processillustrated in the following Scheme II ##STR10##

As used in Scheme II, Q may be N, O or S; R²⁴ is selected from the groupconsisting of hydrogen, R⁴, R⁵, R⁶, and R⁷ ; R²⁵ is selected from thegroup consisting of SOR⁴ and SO₂ R⁴ ; all other meanings are as definedsupra.

Additional compounds of Formula I may be prepared using the processillustrated by Scheme III. ##STR11##

As used in Scheme III, Hal, W, r, and G are as defined supra. As used inScheme III, R²² and R²³ are independently selected from the groupconsisting of hydrogen, R⁶ and R⁷.

Certain intermediates of the present invention may be prepared using theprocess illustrated in Scheme IV. ##STR12##

As used in Scheme IV, R⁸, Si, R¹⁰,R¹¹, R¹², R¹³, R¹⁴, R^(15'), R¹⁵ andR¹⁶ are as defined supra. For example, R⁸ N[(R¹⁰ R¹¹ R¹² Si)(R¹³ R¹⁴R^(15') Si) may be, but is not limited to lithiumbis(tri-2-propylsilyl)amide, sodium bis(trimethylsilyl)amide, potassiumbis(trimethylsilyl)amide, lithium bis(tri-2-propylsilyl)amide, sodiumbis(ethyldimethylsilyl)amide, potassiumbis(1-propylethylmethylsilyl)amide, lithium bis(tri-phenylsilyl)amide,sodium bis(tri-phenylmethylsilyl)amide, potassiumbis(2-butyl-2-propylmethylsilyl)amide, lithium(tri-2-propylsilyl)(2-butyldiethylsilyl)amide, sodium(trimethylsilyl)(triphenytsilyl)amide, potassium (dimethylphenylsilyl)(ethyldimethylsilyl)amide, and the like. Most preferably,R¹⁵ and R¹⁶ are each hydrogen when the process of Scheme III is used forpreparing a compound of 11 from a compound of 10. The intermediate 10may be nitrosated using standard nitrosating procedures. A preferrednitrosating agent is isoamyl nitrite; however, other known nitrosatingagents are appropriate. As used in Scheme III, the term "Cu(Br, I)"refers to copper (I) bromide, copper (II) bromide, or copper (I) iodide.The artisan will recognize that the copper (I) bromide, copper (II)bromide, or copper (I) iodide reagent shall determine the substitutionon the product of the process illustrated in Scheme III.

Certain compounds of this invention may more preferably be prepared by aprocess using a hydroxyalkylamine (G--OH) wherein G has the meaningdefined supra. in the presence of a phosphorus(III) compound and adiester of azodicarboxylate to give the 1,2,5-thiadiazoyloxyalkylamineas illustrated by Scheme V. ##STR13##

The G groups are as defined supra. The R' is selected from the groupconsisting of hydrogen, halogen, NR⁶ R⁷, R⁴, --OR⁴, --SR⁴, --SOR⁴, --SO₂R⁴, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀ -cycloalkyland --Z--C₄₋₁₂ -(cycloalkylalkyl);

R⁴ is selected from the group consisting of C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, C₂₋₁₅ -alkynyl, each of which is optionally substituted withone or more independently selected from the group consisting ofhalogen(s), --CF₃, --CN, Y, phenyl and phenoxy wherein phenyl or phenoxyis optionally substituted with one or more independently selected fromthe group consisting of halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy,--OCF₃, or --CF₃, or

R' is phenyl or benzyloxycarbonyl, each of which is optionallysubstituted with one or more independently selected from the groupconsisting of halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃, and--CF₃ ; or

R' selected from the group consisting of --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y,--SR⁵ ZY, --O--R⁵ --Z--R⁴ and --S--R⁵ --Z--R⁴ ;

Z is oxygen or sulphur;

R⁵ is selected from the group consisting of C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, and C₂₋₁₅ -alkynyl;

Y is a 5 or 6 membered heterocyclic group;

R^(1') is selected from the group consisting of phenyl, C₁₋₁₅ -alkyl,C₂₋₅ -alkenyl, C₂₋₅ -alkynyl and (NR^(2'))₃ ;

R^(2') and R^(3') are independently selected from the group consistingof hydrogen, C₁₋₁₅ -alkyl, C₂₋₅ -alkenyl, C₂₋₅ -alkynyl, and C₁₋₅ -alkylsubstituted with one or more selected from the group consisting ofhalogen and phenyl;

W is oxygen or sulphur;

R⁶, and R⁷ independently are C₁₋₆ -alkyl; or

R⁶ and R⁷ together with the nitrogen atom optionally form a 4- to6-member ring;

R¹ and R² are independently selected from hydrogen, C₁₋₁₅ -alkyl, C₂₋₅-alkenyl, C₂₋₅ -alkynyl, C₁₋₁₀ -alkoxy, and C₁₋₅ -alkyl substituted withone or more independently selected from the group consisting of--COR^(6'), halogen, and phenyl;

R^(6') is hydrogen or C₁ -C₃ alkyl;

R³ is selected from the group consisting of C₁₋₅ -alkyl, C₂₋₅ -alkenyland C₂₋₅ -alkynyl;

n is 0, 1 or 2;

m is 0, 1 or 2;

p is 0, 1 or 2;

q is 1 or 2;

r is 0, 1 or 2;

. . . . . . . is a single or double bond.

Preferred R^(1') groups include phenyl, C₁₋₁₅ -alkyl, and (NR^(2'))₃.The process of Scheme IV is particularly advantageous because theprocess provides a method for inverting the stereochemistry at thecarbon bearing the hydroxyl group in G.

Another new process illustrated by Scheme VI, involves the sequentialreaction of 3,4-dihydroxy-1,2,5-thiadiazole with G--OH wherein G isdefined as defined supra. in the presence of a phosphorous(III)compounds and a diester of azodicarboxylate to give an unisolatedhydroxy-1,2,5-thiadiazole ether I" followed by reaction of I" with R⁴ OHwhere R⁴ is defined as supra. with phosphorous(III) compounds and adiester of azodicarboxylate to give the diethers of3,4-dihydroxy-1,2,5-thiadiazole which are useful as muscarinic agonistsand antagonists. (See, Org. Prep. & Procedures 1969, 1, 255-258) Thesubstituents illustrated in Scheme VI are as defined supra. ##STR14##

Alternatively, the order of addition of the alcohols may be reversed asshown above to give unisolated hydroxy-1,2,5-thiadiazole ether II whichis subsequently converted to the same final muscarinic active compound.

The process illustrated by Scheme VII encompases the reaction of aphenol or hydroxyheteroaryl compound with compound III in the presenceof a phosphorus(III) compound and a diester of azodicarboxylate to givecompound IV. ##STR15##

In compound III, G(CH₂)_(r) W is as defined supra. and R^(6') isselected from the group consisting of R⁷, --OR⁷, --SR⁷, --SOR⁷, --SO₂R⁷, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀ -cycloalkyland --Z--C₄₋₁₂ -(cycloalkylalkyl);

R⁷ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl, each of which isoptionally substituted with one or more independently selected from thegroup consisting of halogen(s), --CF₃, --CN, Y, phenyl and phenoxy;wherein phenyl or phenoxy is optionally substituted with one or moreselected from the group consisting of halogen, --CN, C₁₋₄ -alkyl, C₁₋₄-alkoxy, --OCF₃, and --CF₃ ;

provided that at least one alkyl atom of R^(6') is substituted with ahydroxyl group or R^(6') is a substituent selected from the groupconsisting of --OR⁸ Y, --SR⁸ Y, OR⁸ --Z--Y, --SR⁸ ZY, --O--R⁸ --Z--R⁷and --S--R⁸ --Z--R⁷ wherein each --OR⁸ Y, --SR⁸ Y, OR⁸ --Z--Y, --SR⁸ ZY,--O--R⁸ --Z--R⁷ and --S--R⁸ --Z--R⁷ is substituted with a alkylhydroxyl;

Y is a 5 or 6 membered heterocyclic group;

Z is oxygen or sulphur;

R⁸ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl; aryl and heteroarylis optionally substituted with one or more independently selected fromthe group consisting of halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, C₁₋₄-alkylthio, C₁₋₄ -alkylsulfone, C₁₋₄ -alkylsulfoxide, --OCF₃, NO₂,N(R⁷)₂, and --CF₃ ; heteroaryl group is a 5 or 6 membered heterocyclecontaining one to four N, O, or S atoms or a combination thereof.

Another process of this invention, illustrated by Scheme VIII, is thesynthesis of 3-hydroxy-4-alkylthio-1,2,5-thiadiazoles by treating3-halo-4-alkylthio-1,2,5-thiadiazoles with aqueous alkaline metalhydroxides in the presence or absence of a dipolar aprotic solvent. Inthis scheme, Hal has the meanings defined supra. and M is an alkalimetal, W is O or S. ##STR16##

R^(R) is hydrogen, R⁴, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), R⁴--Z--C₃₋₁₀ -cycloalkyl and R⁴ --Z--C₄₋₁₂ -(cycloalkylalkyl);

R⁴ is selected from the group consisting of C₁₋₁₅ -alkyl, C₂₋₁₅-alkenyl, and C₂₋₁₅ -alkynyl, each of which is optionally substitutedwith one or more independently selected from the group consisting ofhalogen(s), --CF₃, Y, phenyl and phenoxy; wherein phenyl or phenoxy isoptionally substituted with one or more selected from the groupconsisting of halogen, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, and --CF₃ ; or

R^(R) is phenyl or benzyloxycarbonyl, each of which is optionallysubstituted with one or more selected from the group consisting ofhalogen, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, and --CF₃ ; or

R^(R) is R⁴ --OR⁵ Y, R⁴ --SR⁵ Y, R⁴ --OR⁵ --Z--Y, R⁴ --SR⁵ ZY, R⁴--O--R⁵ --Z--R⁴ or R⁴ --S--R⁵ --Z--;

Z is oxygen or sulphur;

R⁵ is selected from the group consisting of C₁₋₁₅ -alkyl,

C₂₋₁₅ -alkenyl, and C₂₋₁₅ -alkynyl;

Y is a 5 or 6 membered heterocyclic group; and

R⁶, and R⁷ independently are hydrogen, C₁₋₆ -alkyl, or R⁶ and R⁷together with the nitrogen atom optionally form a 4- to 6-member ring;

R¹ and R² independently are hydrogen, C₁₋₁₅ -alkyl, C₂₋₅ -alkenyl, C₂₋₅-alkynyl, C₁₋₁₀ -alkoxy, C₁₋₅ -alkyl substituted with --OH, --COR^(6'),CH₂ --OH, halogen, --NH₂, carboxy, or phenyl;

R^(6') is hydrogen or C₁ -C₃ alkyl; W is O or S;

Hal is selected from Cl, Br, F, I, and if W is O then Hal may be SO₂R^(4') ;

R^(4') is C₁ -C₃ alkyl or phenyl.

The compounds (11) are useful intermediates for the preparation of1,2,5-thiadiazole compounds. The artisan will recognize that theintermediates 11 are useful for preparing 1,2,5-thiadiazole compounds asillustrated by the processes of Schemes I, II, and III.

When the G substituent contains a secondary nitrogen protected by aprotecting group, the protecting group may be removed using standardmethods known to the skilled artisan. An especially preferred protectinggroup is carbamate. One particularly useful reference concerningprotecting groups is Greene, Protecting Groups in Organic Synthesis,(John Wiley & Sons, New York, 1981).

The concentration of the reactants is not critical. The art worker canalter the concentration of the reactants to achieve the desired rate ofreaction and product yield.

The length of time for carrying out the processes described are notcritical. As is always the case in chemistry, the rate of the reactiondepends on a variety of factors, such as the temperature and the exactcompound which is to be prepared. The course of the reaction may befollowed using methods such as thin layer chromatography (TLC), highperformance liquid chromatography (HPLC), gas chromatography (GC) andnuclear magnetic resonance spectroscopy (NMR) to detect the degree ofcompletion of the reaction. The operator may obtain maximum yields usingthe process by extending the reaction time. Alternatively, the operatormay wish to obtain maximum throughput by cutting off the reaction at thepoint at which it reaches an economical degree of completion.

When the product of a step in the following process is an oil, it may beisolated by standard methods. Such methods include distillation, flashchromatography, HPLC and the like.

As used herein the term "malfunctioning of the muscarinic cholinergicsystem" shall have the meaning accepted by the skilled artisan. Forexample the term shall refer to, but is not in any way limited to,conditions such as glaucoma, psychosis, schizophrenia orschizophreniform conditions, depression, sleeping disorders, epilepsy,and gastrointestinal motility disorders. Other such conditions includeAlzheimer's Disease and incontinence.

The pharmacological properties of the compounds of the invention can beillustrated by determining their capability to inhibit the specificbinding of ³ H-Oxotremorine-M (³ H-Oxo). Birdsdall N. J. M., Hulme E.C., and Burgen A. S. V. (1980). "The Character of Muscarinic Receptorsin Different Regions of the Rat Brain" Proc. Roy. Soc. London (Series B)207,1.

³ H-Oxo labels muscarinic receptor in the CNS (with a preference foragonist domains of the receptors). Three different sites are labeled by³ H-Oxo. These sites have affinity of 1.8, 20 and 3000 nM, respectively.Using the present experimental conditions only the high and mediumaffinity sites are determined.

The inhibitory effects of compounds on ³ H-oxo binding reflects theaffinity for muscarinic acetylcholine receptors.

All preparations are performed at 0°-4° C. unless otherwise indicated.Fresh cortex (0.1-1 g) from male Wistar rats (150-250 g) is homogenizedfor 5-10 seconds in 10 mL 20 nM Hepes pH: 7.4, with an Ultra-Turraxhomogenizer. The homogenizer is rinsed with 10 mL of buffer and thecombined suspension centrifuged for 15 min. at 40,000×g. The pellet iswashed three times with buffer. In each step the pellet is homogenizedas before in 2×10 mL of buffer and centrifuged for 10 min. at 40,000×g.

The final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g oforiginal tissue) and used for binding assay. Aliquots of 0.5 mL is added25 μL of test solution and 25 μL of ³ H-Oxotremorine (1.0 nM, finalconcentration) mixed and incubated for 30 min. at 25° C. Non-specificbinding is determined in triplicate using arecoline (1 μgL, finalconcentration) as the test substance. After incubation samples are added5 mL of ice-cold buffer and poured directly onto Whatman GF/C glassfiber filters under suction and immediately washed 2 times with 5 mL ofice-cold buffer. The amount of radioactivity on the filters aredetermined by conventional liquid scintillation counting. Specificbinding is total binding minus non specific binding.

Test substances are dissolved in 10 mL water (if necessary heated on asteam-bath for less than 5 min.) at a concentration of 2.2 mg/mL. 25-75%inhibition of specific binding must be obtained before calculation ofIC₅₀. The test value will be given as IC₅₀ (the concentration (nM) ofthe test substance which inhibits the specific binding of ³ H-oxo by50%). IC₅₀ =(applied test substance concentration) x(C_(x) /C_(o)-C_(x))nM where C_(o) is specific binding in control assays and C_(x) isthe specific binding in the test assay. (The calculations assume normalmass-action kinetics).

Furthermore the pharmacological properties of the compounds of theinvention can also be illustrated by determining their capability toinhibit ³ HPRZ (pirenzepine, [N-methyl-³ H]) binding to rat cerebralcortex membranes.

Pirenzepine binds selectively to subtype of muscarinic receptors.Historically the type is named the M₁ -site, whereas pirenzepinesensitive site would be more appropriate. Although selective for M₁-sites pirenzepine also interact with M₂ -sites.

All preparations are performed at 0°-4° C. unless otherwise indicated.Fresh cortex (0.1-19) from male Wistar rats (150-200 g) is homogenizedfor 5-10 s in 10 mL 20 mM Hepes pH: 7.4, with an Ultra-Turraxhomogenizer. The homogenizer is rinsed with 2×10 mL of buffer and thecombined suspension centrifuged for 15 min. at 40,000×g. The pellet iswashed three times with buffer. In each step the pellet is homogenizedas before in 3×10 mL of buffer and centrifuged for 10 min. at 40,000×g.

The final pellet is homogenized in 20 mM Hepes pH: 7.4 (100 mL per g oforiginal tissue) and used for binding assay. Aliquots of 0.5 mL is added20 μl of test solution and 25 μL of ³ HPRZ (1.0 nM, final conc.), mixedand incubated for 60 min. at 20° C. Non-specific binding is determinedin triplicate using atropine (1 ,μg/mL, final conc.) as the testsubstance. After incubation samples are added 5 mL of ice-cold bufferand poured directly onto Whatman GF/C glass fiber filters under suctionand immediately washed 2 times with 5 mL of ice-cold buffer. The amountof radioactivity on the filters are determined by conventional liquidscintillation counting. Specific binding is total binding minusnon-specific binding.

Test substances are dissolved in 10 mL water, at a concentration of 0.22mg/mL. 25-75% inhibition of specific binding must be obtained beforecalculation of IC₅₀.

The test value will be given as IC₅₀ (the concentration (nM) of the testsubstance which inhibits the specific binding of ³ HPRZ by 50%). IC₅₀=(applied test substance concentration) x(C_(x) /C_(o) -C_(x))nM whereC_(o) is specific binding in control assays and C_(x) is the specificbinding in the test assay. (The calculations assume normal mass-actionkinetics).

Test results obtained by testing some compounds of the present inventionwill appear from the following table 1.

                  TABLE 1                                                         ______________________________________                                                       .sup.3 H-Oxo                                                                           .sup.3 HPRZ                                           Compound       IC.sub.50, nM                                                                          IC.sub.50, nM                                         ______________________________________                                        12             73       86                                                    5              162      183                                                   6              17       32                                                    7              10.7     26                                                    8              3.1      7.4                                                   9              11       25                                                    10             6.1      22                                                    11             29       33                                                    13             1.4      3.7                                                   14             1.3      1.9                                                   15             1.6      2.3                                                   17             5.2      8.8                                                   18             101      73                                                    33             51       48                                                    35             23       33                                                    36             204      217                                                   31             32       12                                                    27             123      370                                                   28             37       25                                                    30             69       19                                                    26             11       37                                                    25             1.8      2.1                                                   29             34       20                                                    34             86       10                                                    22             23       7.4                                                   23             55       18                                                    24             19       19                                                    32             77       45                                                    19             0.36     7.5                                                   20             2.6      4                                                     21             4.4      4                                                     16             6.4      2                                                     38             1        1.9                                                   39             13       15                                                    40             1.8      2.5                                                   41             25       19                                                    42             14       9.3                                                   43             29       33                                                    44             7.1      15                                                    46             >1000    >1000                                                 47             54       23                                                    48             14       27                                                    49             1.8      1.9                                                   50             92       351                                                   51             25       112                                                   52             >1000    475                                                   53             24       35                                                    55             11       23                                                    57             88       37                                                    59             104      102                                                   60             19       14                                                    61             1.1      5.8                                                   45             29       4.6                                                   69             29       20                                                    65             2.3      0.72                                                  70             1.3      0.65                                                  71             1.1      1.15                                                  72             1.9      0.55                                                  ______________________________________                                                       Oxo-M    Pir                                                   Compound #     IC-50, nM                                                                              IC-50 nM                                              ______________________________________                                        73             4.1      6.5                                                   74             24       40                                                    75             65       128                                                   99             41       70                                                    100            873      846                                                   101            88       36                                                    102            378      187                                                   103            107      115                                                   104            107      115                                                   105            7.9      65.6                                                  106            9.5      95.4                                                  107            9.6      22.4                                                  108            9.1      56.1                                                  109            12.3     58.3                                                  110            13.2     50.4                                                  111            38       85                                                    112            16       153                                                   113            3.6      23                                                    114            9.3      43                                                    115            19       532                                                   116            14       33                                                    117            32       238                                                   118            7.2      70                                                    119            17       124                                                   120            11       71                                                    121            12       146                                                   122            11       45                                                    123            42       106                                                   124            5.8      54                                                    125            36       191                                                   126            19       72                                                    127            61       373                                                   128            6.9      109                                                   129            nd       nd                                                    131            5.6      46                                                    132            11       66                                                    133            >1000    >1000                                                 134            55       227                                                   135            >1000    >1000                                                 136            2.73     6.42                                                  137            7.39     2.10                                                  138            0.65     0.47                                                  139            230      145                                                   142            38       74                                                    143            1399     637                                                   144            12       9                                                     146            775      >1000                                                 147            1.1      1.15                                                  148            8        25                                                    207            2.4      6                                                     149            14       30                                                    150            17       36                                                    151            2071     2702                                                  152            436      243                                                   153            597      205                                                   154            11       6.3                                                   155            3.4      8.8                                                   156            1        0.6                                                   160            14       6.3                                                   161            6.8      5.3                                                   162            179      128                                                   164            5.28     16.64                                                 167            2.8      2.0                                                   168            1.0      6.4                                                   169            1.0      1.9                                                   170            1.5      3.0                                                   171            19       27                                                    172            5.2      10                                                    173            1.0      1.4                                                   174            2.1      12                                                    175            0.74     2.7                                                   176            1.3      3.0                                                   177            1.1      2.0                                                   178            15       61                                                    180            4.7      11                                                    181            1.1      2.2                                                   182            0.6      3.5                                                   183            2.6      9.9                                                   184            1.2      2.2                                                   185            0.76     2.0                                                   186            0.59     2.8                                                   187            2.8      1.6                                                   188            12       43                                                    189            1.7      3.8                                                   190            3.9      2.5                                                   191            1.4      9.5                                                   192            13       21                                                    193            3.7      10                                                    194            2.1      4                                                     195            4.9      7.5                                                   196            5.2      8.8                                                   197            2.3      6.9                                                   198            31       120                                                   199            3.3      5.4                                                   200            16       12                                                    201            3.7      3.1                                                   202            13       31                                                    203            3.1      4.3                                                   204            59       153                                                   205            2.5      3.0                                                   206            6.1      5.0                                                   ______________________________________                                    

`nd` as used herein refers to values not yet determined.

Table II illustrates several additional formula I compounds as claimedherein.

                                      TABLE II                                    __________________________________________________________________________    R       W  r G*    R.sup.1 *                                                                              R.sup.2 *                                                                          R.sup.3                                                                            n  m  p/g**                             __________________________________________________________________________    H       S  0 het-6 H        CH.sub.3                                                                           --   1  1  2                                              (C-2)          C-3                                               Cl      S  1 het-5 CH.sub.3 H    H    -- -- --                                             (C-2) C-3                                                        Br      O  2 het-6 CH.sub.2 OH                                                                            H    --   1  1  2                                              (C-3) C-2                                                        NH.sub.2                                                                              O  1 het-4 CH.sub.2 COOH.sub.3                                                                    H    H    -- 1  1                                              (C-3) C-4                                                        NHC.sub.2 H.sub.5                                                                     S  0 het-3 (uns)                                                                         CH═CH.sub.2                                                                        CH.sub.3                                                                           CH   1  2  0                                              (C-3) C-4      C-2                                               NCH.sub.3 CH.sub.3                                                                    O  0 het-7 (uns)                                                                         C.sub.2 H.sub.3 (CH.sub.2 OH)CH.sub.3                                                  H    C.sub.2 H.sub.5                                                                    -- 2  1                                              (C-3) C-5                                                        --NHCH.sub.3                                                                          S  0 het-1 CH.sub.3 H    CH.sub.3                                                                           -- -- --                                             (C-3) C-2                                                        --Br    O  1 het-2 (sat)                                                                         H        H    C.sub.2 H.sub.5                                                                    -- -- --                                             (C-4)                                                            --I     O  2 het-6 H        C.sub.6 H.sub.13                                                                   --   2  0  1                                              (C-4)          C-3                                               --OCH.sub.3                                                                           S  0 het-1 CHCl     H    H    -- -- --                                             (C-3) C-3                                                        --SC.sub.2 H.sub.5                                                                    S  1 het-2 (uns)                                                                         CHNH.sub.2                                                                             CHBr CH.sub.3                                                                           -- -- --                                             (C-3) C-2      C-4                                               --SOCH═CH.sub.2                                                                   O  0 het-3 (sat)                                                                         CHC(O)OH H    CH═CH.sub.2                                                                    0  2  2                                              (C-4) C-3                                                        cyclohexyl                                                                            S  1 het-4 CH.sub.3 CH.sub.3                                                                           H    -- 1  1                                              (C-4) C-4      C-5                                               cyclopentyl                                                                           O  0 het-6 C.tbd.C.sub.2 H.sub.3                                                                  H    --   0  2  1                                 methyl-      (C-5) C-4                                                        --S-cyclo-                                                                            S  2 het-7 (sat)                                                                         CH.sub.3 C.sub.2 H.sub.5                                                                    H    -- 1  0                                 butyl        (C-4) C-3      C-6                                               --O-cyclo-                                                                            O  0 het-5 H        H    H    -- -- --                                propylethyl  (C-3)                                                            OC.sub.2 H.sub.5 (CH.sub.3)Cl                                                         S  1 het-7 (uns)                                                                         OC.sub.2 H.sub.5 H                                                                     H    H    -- 0  2                                              (C-5) C-4                                                        __________________________________________________________________________     *As used in Table I, the Cnumber in the second row of the description of      each compound refers to the point of attachment on the ring for the           indicated variable.                                                           **As used in Table I, the p/q column refers to the value for the              appropriate variable for the designated G value. For example when G is        het7, the p/q column provides the value for q.                           

The compounds of the invention arc effective over a wide dosage range.For example, in the treatment of adult humans, dosages from about 0.05to about 100 lug, preferably from about 0.1 to about 100 mg, per day maybe used. A most preferable dosage is about 0.1 mg to about 70 mg perday. In choosing a regimen for patients suffering from diseases in thecentral nervous system caused by malfunctioning of the muscariniccholinergic system it may frequently be necessary to begin with a dosageof from about 20 to about 70 mg per day and when the condition is undercontrol to reduce the dosage as low as from about 0.1 to about 10 mg perday. The exact dosage will depend upon the mode of administration, formin which administered, the subject to be treated and the body weight ofthe subject to be treated, and the preference and experience of thephysician or prescribing caregiver in charge.

The route of administration may be any route, which effectivelytransports the active compound to the appropriate or desired site ofaction, such as oral or parenteral e.g. rectal, transdermal, depot,subcutaneous, intravenous, intramuscular or intranasal, the oral routebeing preferred.

Typical compositions include a compound of formula I or apharmaceutically acceptable acid addition salt thereof, associated witha pharmaceutically acceptable excipient which may be a carrier, or adiluent or be diluted by a carrier, or enclosed within a carrier whichcan be in the form of a capsule, sachet, paper, or other container. Inmaking the compositions, conventional techniques for the preparation ofpharmaceutical compositions may be used. For example, the activecompound will usually be mixed with a carrier, or diluted by a carrier,or enclosed within a carrier which may be in the form of a ampoule,capsule, sachet, paper, or other container. When the carrier serves as adiluent, it may be solid, semi-solid, or liquid material which acts as avehicle, excipient, or medium for the active compound. The activecompound can be adsorbed on a granular solid container for example in asachet. Some examples of suitable carriers are water, salt solutions,alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil,gelatine, lactose, amylose, magnesium stearate, talc, silicic acid,fatty acid monoglycerides and diglycerides, pentaerythritol fatty acidesters, hydroxymethylcellulose and polyvinylpyrrolidone. Theformulations may also include wetting agents, emulsifying and suspendingagents, preserving agents, sweetening agents, or flavoring agents. Theformulations of the invention may be formulated so as to provide quick,sustained, or delayed release of the active ingredient afteradministration to the patient by employing procedures well known in theart.

The pharmaceutical preparations can be sterilized and mixed, if desired,with auxiliary agents, emulsifiers, salt for influencing osmoticpressure, buffers and/or coloring substances and the like, which do notdeleteriously react with the active compounds.

For parenteral application, particularly suitable are injectablesolutions or suspensions, preferably aqueous solutions with the activecompound dissolved in polyhydroxylated castor oil.

Tablets, dragees, or capsules having talc and/or a carbohydrate carrieror binder or the like are particularly suitable for oral application.Preferable carriers for tablets, dragees, or capsules include lactose,corn starch, and/or potato starch. A syrup or elixir can be used incases where a sweetened vehicle can be employed.

Generally, the compounds are dispensed in unit form comprising fromabout 0.1 to about 100 mg in a pharmaceutically acceptable carrier perunit dosage.

The compounds of this invention may be suitable for administration to ananimal. Such animals include both domestic animals, for examplelivestock, laboratory animals, and household pets, and non-domesticanimals such as wildlife. More preferredly, the animal is a vertebrate.Most preferredly, a compound of this invention shall be administered toa mammal. It is especially preferred that the animal is a domesticmammal or a human. The most preferred mammal is a human. For suchpurposes, a compound of this invention may be administered as a feedadditive.

In order to more fully illustrate the operation of this invention, thefollowing formulation examples are provided. The examples areillustrative only, and are not intended to limit the scope of theinvention in any way.

FORMULATION 1

A typical tablet, appropriate for use in this method, may be preparedusing conventional techniques and may contain:

    ______________________________________                                                      Amount per    Concentration                                     (%)           Tablet        by Weight                                         ______________________________________                                        (±)-Endo-3-butylthio-                                                                    5.0     mg        4.7                                           4-(1-azabicyclo[3.2.1]-                                                       octyl-6-oxy)-1,2,5-                                                           thiadiazole                                                                   Lactosum      67.8    mg Ph. Eur.                                                                             64.2                                          Avicel ®  31.4    mg        29.8                                          Amberlite ®                                                                             1.0     mg        1.0                                           magnesium stearate                                                                          0.25    mg        0.3                                                         105.45  mg        100                                           ______________________________________                                    

FORMULATION 2

Hard gelatin capsules are prepared using the following ingredients:

    ______________________________________                                                          Amount per                                                                             Concentration                                      (%)               Tablet   by Weight                                          ______________________________________                                        (±)-Exo-3-butyloxy-4-                                                                        0.1    mg    0.05                                           (N-methyl-8-azabicyclo-                                                       [3.2.1]octyl-3-oxy)-1,2,5-                                                    thiadiazole                                                                   starch dried      200    mg    95.2                                           magnesium stearate                                                                              10     mg    4.8                                                              210.1  mg    100                                            ______________________________________                                    

The above ingredients are mixed and filled into hard gelatin capsules in210.1 mg quantities.

FORMULATION 3

Suspensions each containing t mg of medicament per 5 mL dose are asfollows:

    ______________________________________                                                          Amount per 5 mL of                                                            suspension                                                  ______________________________________                                        (±)-3-(3-phenylethylthio)-                                                                     1          mg                                             4-(1-azabicyclo[2.2.2]octyl-                                                  3-oxy)-1,2,5-thiadiazole                                                      sodium carboxymethyl cellulose                                                                    50         mg                                             syrup               1.25       mL                                             benzoic acid solution                                                                             0.10       mL                                             flavor              q.v.                                                      color               q.v.                                                      water               q.s. to 5  mL                                             ______________________________________                                    

The medicament is passed through a No. 45 mesh U.S. sieve and mixed withthe sodium carboxymethyl cellulose and syrup to form a smooth paste. Thebenzoic acid solution, flavor and color is diluted with some of thewater and added to the paste with stirring. Sufficient water is thenadded to produce the required volume.

The intermediates and processes of the present invention are useful forpreparing compounds having beneficial muscarinic receptor activity. Thecompounds of the present invention have such useful muscarinic receptoractivity. Certain compounds and conditions within the scope of thisinvention are preferred. The following conditions, inventionembodiments, and compound characteristics listed in tabular form may beindependently combined to produce a variety of preferred compounds andprocess conditions. The following list of embodiments of this inventionis not intended to limit the scope of this invention in any way.

Some prefered characteristics of compounds of formula I are:

A) W is 0;

B) r is 1 or 2;

C) G is selected from her-1 and her-5;

D) G is unsaturated;

E) G is her-4;

F) G is an azabicycle having 7 ring carbon atoms and a nitrogen atom;

G) G is bet-6;

H) r is 0;

I) R is selected from halogen, --OR⁵ Y, --SR⁵ Y, --OR⁵ ZY, --SR⁵ ZY,--OR⁵ ZR⁴, --SR⁵ ZR⁴, --OR⁴, and --SR⁴ ;

J) W is S;

K) m is 1;

L) n is 1;

M) p is 2;

N) V is O or S;

O) G is het-2

P) G is selected from the following heterocycles: ##STR17## the point ofattachment to the --(CH₂)_(r) --W-- group is as indicated;

Q) G groups is selected from the group consisting of ##STR18## R) G isnot an azabicycle; S) G is het-3;

T) R is not OR⁴ wherein R⁴ is C₁ -C₃ alkyl;

U) R⁴ is C₄ -C₁₅ alkyl;

V) G is an azacyclic or azabicyclic group;

W) R is selected from the group consisting of --OR⁵ Y, --SR⁵ Y, OR⁵--Z--Y, --SR⁵ ZY, --O--R⁴ --Z--R⁵ or --S--R⁴ --Z--R⁵, wherein Z isoxygen or sulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl, Yis a 5 or 6 membered heterocyclic group containing one to four N, O or Satom(s) or a combination thereof, R⁴ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl,C₂₋₁₅ -alkynyl;

Especially preferred compounds of formula I have the characteristics ofA-E; characteristics of A, G, H, M; characteristics of G--O; A, H, R; B,I, J; J, K S; A, K, Q; J, P, L; or the characteristics of F,G-J,M.

Some prefered characteristics of the process and intermediates of thisinvention are:

A) W is O;

B) R¹⁵ and R¹⁶ are not each hydrogen;

C) R¹⁰, R¹¹ and R¹² are each methyl;

D) R is selected from the group consisting of phenyl, benzyloxycarbonyl,--OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y, --SR⁵ ZY, --O--R⁴ --Z--R⁵ or --S--R⁴--Z--R⁵, --SOR⁴, C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀-cycloalkyl and --Z--C₄₋₁₂ -(cycloalkylalkyl) wherein Z is oxygen orsulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl, Y is a 5 or6 membered heterocyclic group containing one to four N, O or S atom(s)or a combination thereof, R⁴ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅-alkynyl;

E) R is selected from the group consisting of halogen, --OR⁴, and --SR⁴;

F) G is an azabicycle having 6 ring carbon atoms and a nitrogen atom;

G) R¹⁵ and R¹⁶ are selected from the group consisting of (R¹⁰ R¹¹ R¹²Si) and (R¹³ R¹⁴ R^(15') Si);

H) R¹⁸ is R⁴ SO₂ ;

I) W is S;

J) R is selected from the group of --OR, --SR, and I.

K) R¹⁷ is alkyl or R¹⁹ substituted alkyl;

L) W' is S or SO₂ ;

M) When the compound is of Formula V, the R¹⁸ is R⁴ SO₂, Br or I;

N) R is not OR⁴ wherein R⁴ is C₁ -C₃ alkyl;

O) R⁴ is C₄ -C₁₅ alkyl;

P) G is an azacyclic or azabicyclic group;

Q) R is selected from the group consisting of --OR⁵ Y, --SR⁵ Y, OR⁵--Z--Y, --SR⁵ ZY, --O--R⁴ --Z--R⁵ or --S--R⁴ --Z--R⁵, wherein Z isoxygen or sulphur, R⁵ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl, C₂₋₁₅ -alkynyl, Yis a 5 or 6 membered heterocyclic group containing one to four N, O or Satom(s) or a combination thereof, R⁴ is C₁₋₁₅ -alkyl, C₂₋₁₅ -alkenyl,C₂₋₁₅ -alkynyl;

Especially preferred characteristics of the process and intermediates ofthis invention are A-F; characteristics of B,C,E; characteristics ofH,J,K; K,L,M; or the characteristics of B-F,I.

The invention will now be described in further detail with reference tothe following examples. The examples are provided for illustrativepurposes, and are not to be construed as limiting the scope of theinvention in any way.

EXAMPLE 1 3-Chloro-4-(1-butylthio)-1,2,5-thiadiazole

Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 mL) maintained at-10° C. To the solution was added dropwise diethylamine (3 mL) followedby dropwise addition of 1-butylthiol (47 mL, 0.64 mol) at such a ratethat the temperature did not exceed -5° C. The reaction was maintainedbelow 0° C. for 5 h then stirred at ambient overnight. Ether wasdistilled from the reaction until the pot temperature reached 50° C. Thereaction was cooled to ambient and then added dropwise to a solution ofsulfur monochloride (55 mL, 0,688 mol) in DMF (50 mL) that was cooled to5° C. Cooling was removed and reaction was stirred overnight. Thereaction was cooled in an ice-water bath and excess sulfur monochloridedestroyed by careful addition of H₂ O while maintaining the temperaturebelow 40° C. The liquid was decanted from the semi-solid sulfurprecipitant and the sulfur residue triturated with hexane. The aqueousfraction was extracted with hexane (3×) and the combined extracts andtriturants were washed with H₂ O, aqueous NaHCO₃, brine, dried, and thesolvent evaporated. The residue was distilled at 2 mmHg to give a yellowliquid (24.6 g), b.p. 105°-110° C. (Compound 1).

EXAMPLE 2 3-Chloro-4-butylsulfonyl-1,2,5-thiadiazole

A solution of Oxone™ (12 g, 0.0195 mol) in H₂ O (60 mL) was vigorousstirred as 3-chloro-4-butylthio-1,2,5-thiadiazole (2.1 g, 0.01 mol) inTHF (30 mL) was added dropwise. After 24 h, the THF was evaporated andthe residue extracted with ether (3×). Extracts were washed with H₂ O,dried, and solvent evaporated to give a clear liquid. Radialchromatography eluting with 30% EtOAc/hexane gave a colorless liquid(2.3 g). (Compound 2).

EXAMPLE 3 3-Chloro-4-ethylthio-1,2,5-thiadiazole

Cyanogen (36 g, 0.69 mol) was bubbled into ether (250 mL) maintained at-10° C. To the solution was added dropwise diethylamine (3 mL) followedby dropwise addition of ethanethiol (47 mL, 0.64 mol) at such a ratethat the temperature did not exceed -5° C. The reaction was maintainedbelow 0° C. for 5 h then stirred at ambient temperature overnight. Etherwas distilled from the reaction until the pot temperature reached 50° C.The reaction was cooled to ambient and then added dropwise to a solutionof sulfur monochloride (125 mL, 1.56 mol) in DMF (150 mL) that wascooled to 5° C. Cooling was removed and the reaction was stirredovernight. The reaction was cooled in an EtOH-ice bath as the excesssulfur monochloride was destroyed by dropwise addition of water whilemaintaining the temperature below 35° C. The liquid was decanted fromthe semi-solid sulfur precipitant and the sulfur residue triturated withhexane. The aqueous fraction was extracted with hexane (3×) and thecombined extracts and triturants were washed with H₂ O, aqueous NaHCO₃,brine, dried, and the solvent evaporated. The brown liquid residue wasdistilled at 3 mm Hg to give a yellow liquid (80.2 g), b.p. 91°-96° C.(Compound 3).

EXAMPLE 4 3-Chloro-4-ethylsulfonyl-1,2,5-thiadiazole

A solution of Oxone (84 g, 0.137 mol) in H₂ O (400 mL) was rapidlystirred as 3-chloro-4-ethylthio-1,2,5-thiadiazole (12.2 g, 0.067 mol) inTHF (200 mL) was added. After stirring overnight, the THF was evaporatedand the residue extracted with ether (3×). The extracts were washed withH₂ O, aqueous NaHCO₃, and brine then the solvent dried and evaporated togive a clear liquid (13.6 g). (Compound 4).

EXAMPLE 5(±)-3-Methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.36 g, 0.0104 mol) in THF(20 mL) was treated dropwise with 1.6M n-butyllithium in hexane (7.4 mL,0.0118 mol). To this solution was added3-methoxy-4-methanesulfonyl-1,2,5-thiadiazole (2.08 g, 0.0107 mol) inTHF (40 mL), the reaction heated to 40° C. for 2 h, and then stirred atambient temperature overnight. The solvent was evaporated, the residueacidified with 1N HCl, and the mixture extracted with ether. The aqueoussolution was made basic and extracted with EtOAc. The extracts werewashed with H₂ O, dried, and the solvent evaporated. The residue waspurified by radial chromatography (2.5% EtOH-0.25% NH₄ OH--CHCl₃) togive a clear oil. The HCl salt of the oil (0.85 g) crystallized fromMeOH-EtOAc, m.p. 197°-198° C. (Compound 5).

EXAMPLE 6(±)-3-Ethoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF(50 mL) was treated dropwise with 1.6M n-butyllithium in hexane (3.7 mL,0.0059 mol). To this solution was added3-ethoxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0048 mol) in THF(12 mL) and the reaction heated to 60° C. for 5 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withether. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. The HCl salt of the oil (0.47 g)crystallized from 2-propanol, m.p. 212°-213° C. (Compound 6).

EXAMPLE 7(±)-3-propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.1 g, 0.0087 mol) in THF(75 mL) was treated dropwise with 1.6M n-butyllithium in hexane (5.0 mL,0.008 mol). To this solution was added3-propyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.3 g, 0.0059 mol) inTHF (15 mL) and the reaction heated to 60° C. for 4 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withEtOAc. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. The HCl salt of the oil (0.59 g)crystallized from 2-propanol, m.p. 218°-219° C. (Compound 7).

EXAMPLE 8(±)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (2.2 g, 0.0168 mol) in THF(25 mL) was treated dropwise with 1.6M n-butyllithium in hexane (10.8mL, 0.0173 mol). To this solution was added3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.98 g, 0.084 mol) inTHF (25 mL) and the reaction heated to 52° C. for 3.5 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withEtOAc. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. The HCl salt of the oil (2.0 g)crystallized from CHCl₃ -EtOAc-ether, m.p. 204°-205° C. (Compound 8).

EXAMPLE 9(±)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF(50 mL) was treated dropwise with 1.6M n-butyllithium in hexane (3.7 mL,0.0059 mol). To this solution was added3-pentyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.004 mol) inTHF (10 mL) and the reaction heated to 60° C. for 4 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withether. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. The HCl salt of the oil (0.75 g)crystallized from EtOAc, m.p. 171°-172° C. (Compound 9).

EXAMPLE 10(±)-3-Hexyloxy-4-(1-azabicyclo[2.2,2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (2.2 g, 0.0168 mol) in THF(25 mL) was treated dropwise with 1.6M n-butyllithium in hexane (10.8mL, 0.0173 mol). To this solution was added3-hexyloxy-4-methanesulfonyl-1,2,5-thiadiazole (2.2 g, 0.004 mol) in THF(25 mL) and the reaction heated to 52° C. for 3.5 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withether. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. The HCl salt of the oil (1.76 g)crystallized from EtOAc, m.p. 165°-166° C. (Compound 10).

EXAMPLE 11(±)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (0.75 g, 0.0059 mol) in THF(50 mL) was treated dropwise with 1.6M n-butyllithium in hexane (3.7 mL,0.0059 mol). To this solution was added3-(4-methylpentyloxy)-4-methanesulfonyl-1,2,5-thiadiazole (1.2 g, 0.0045mol) in THF (10 mL) and the reaction heated to reflux for 6 h. Thesolvent was evaporated, the residue acidified with 1N HCl, and themixture extracted with ether. The aqueous solution was made basic andextracted with ether. The extracts were washed with H₂ O, dried, and thesolvent evaporated to give a clear oil. The HCl salt of the oil (1.1 g)crystallized from EtOAc, m.p. 179°-180° C. (Compound 11).

EXAMPLE 12(±)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.1 g, 0.0084 mol) in THF(25 mL) was treated dropwise with 1.6M n-butyllithium in hexane (5.4 mL,0.0086 mol). This solution was added dropwise to a solution of3-chloro-4-butylsulfonyl-1,2,5-thiadiazole (2.1 g, 0.0086 mol) in THF(15 mL) at such a rate that the temperature did not exceed 32° C. Afterstirring for 3 days, the reaction was treated with H₂ O (10 mL), dilutedwith ether (100 mL), and extracted with 1N HCl (25 mL). The aqueoussolution was washed with ether, made basic, and extracted with ether.The extracts were dried, the solvent evaporated, and the residuepurified by radial chromatography (2.5% EtOH-0.25% NH₄ OH--CHCl₃) togive a straw colored liquid (1.1 g). The oxalate salt (0.39 g)crystallized from MeOH-EtOAc, m.p. 154°-156° C. (Compound 12).

Alternative Synthesis of(±)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 1-azabicyclo[2.2.2]octan-3-ol (1.2 g, 0.0092 mol) in THF(25 mL) was treated dropwise with 1.6M n-butyllithium in hexane (5.9 mL,0.0095 mol). The solution was cooled to -8° C. and a solution of3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF(15 mL) was added dropwise. After 15 min, cooling was removed and thereaction stirred overnight. The reaction was treated with H₂ O (10 mL),diluted with ether (100 mL), and extracted with 1N HCl (25 mL). Theaqueous solution was washed with ether, made basic, and extracted withether. The extracts were dried and the solvent evaporated to give crude(compound 12) (1.05 g) as a brownish liquid.

Alternative Synthesis of(±)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A mixture of 1-azabicyclo[2.2.2]octan-3-ol (12.7 g, 0.1 mol),triethylamine (0.3 mL), and CHCl₃ (150 mL) was cooled to 5° C. andcyanogen (7.25 g, 0.139 mol) bubbled into the mixture. The reaction wasstirred another hour then allowed to come to ambient temperatureovernight. The solvent was evaporated, the residue dissolved in DMF (20mL), and the solution added dropwise to a solution of S₂ Cl₂ (47.3 g,0.35 mol) in DMF (30 mL) that was cooled in an ice-water bath. Afteraddition, cooling was removed and reaction exothermed to 32° C. After 5h, reaction cooled and excess S₂ Cl₂ destroyed by careful addition of H₂O. The reaction was diluted with more H₂ O (300 mL) and the aqueoussolution decanted from the sulfur residue. The sulfur residue wastriturated with H₂ O and the combined aqueous solutions evaporated to asmall volume (150 mL). The solution was washed with ether and then madebasic with 50% NaOH while maintaining the temperature below 30° C. Themixture was extracted with CHCl₃, the extracts dried, and the solventsthoroughly evaporated. The residue was suspended in ether, dried,filtered and the solvent evaporated to give (compound 12) (18.1 g) as ayellow oil that slowly solidified.

EXAMPLE 13(±)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude compound 12 (1.67 g, 0.0068 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.8 g,0.0075 mol). After 40 min, 1-bromopropane (1.25 g, 0.010 mol) was addedand the reaction stirred overnight. The solvent was evaporated, theresidue was acidified with 1N HCl, and the mixture extracted with ether.The aqueous was made basic and extracted with ether. The extracts weredried and the solvent evaporated to give a straw-colored liquid. The HClsalt (1.28 g) crystallized from CHCl₃ -EtOAc-ether, m.p. 174°-176° C.(Compound 13).

EXAMPLE 14(±)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.94 g,0.0081 mol). After 1 h, 1-iodobutane (2 g, 0.011 mol) was added and thereaction stirred overnight. The solvent was evaporated, the residue wasacidified with 1N HCl, and the mixture extracted with ether. The aqueouswas made basic and extracted with ether. The extracts were dried and thesolvent evaporated to give a straw-coloured liquid. The HCl salt (1.82g) crystallized from CHCl₃ -EtOAc-ether, m.p. 151°-153° C. (Compound14).

EXAMPLE 15(±)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude compound 12 (1.67 g, 0.0068 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.8 g,0.0075 mol). After 1 h, 1-bromopentane (1.53 g, 0.010 mol) was added andthe reaction stirred overnight. The solvent was evaporated, the residuewas acidified with 1N HCl, and the mixture extracted with ether. Theaqueous was made basic and extracted with ether. The extracts were driedand the solvent evaporated to give a straw-coloured liquid. The HCl salt(1.07 g) crystallized from CHCl₃ -EtOAc-ether, m.p. 186°-187° C.(Compound 15).

EXAMPLE 16(S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of (S)-1-azabicyclo[2.2.2]octan-3-ol (2.0 g, 0.0157 mol) inTHF (40 mL) was cooled to 10° C. as 1.6M n-butyllithium in hexane (10mL, 0.016 mol) was added dropwise. The resulting mixture was treatedwith 3-chloro-ethylsulfonyl-1,2,5-thiadiazole (3.34 g, 0.0157 mol) inTHF (25 mL) and stirred for 16 h. The reaction was treated with H₂ O (10mL), ether (170 mL) and extracted with 1N HCl (43 mL). The aqueousfraction was washed with ether, made basic, and extracted with ether.The extracts were dried and the solvent evaporated to give an oil (1.7g). The oil was dissolved in DMF (25 mL), treated portionwise withfreshly ground flaked Na₂ S-9H₂ O (1.83 g, 0.0076 mol), and heated (40°C.). After 1.25 h, 1-bromopentane (1.58 g, 0.0105 mol) was added and thereaction stirred overnight. The solvent was evaporated, the residue wasacidified with 1N HCl, and the mixture extracted with ether. The aqueouswas made basic and extracted with ether. The extracts were dried and thesolvent evaporated to give a straw-colored liquid that was purified byradial chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃). The HCl salt (0.87g) crystallized from CHCl₃ -EtOAc-ether, m.p. 194°-195° C., [α]_(D)=25.41° (EtOH). (Compound 16).

EXAMPLE 17(±)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude compound 12 (1.8 g, 0.0073 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.94 g,0.0081 mol). After 1 h, 1-iodohexane (2.3 g, 0.011 mol) was added andthe reaction stirred overnight. The solvent was evaporated, the residuewas acidified with 1N HCl, and the mixture extracted with ether. Theaqueous was made basic and extracted with ether. The extracts were driedand the solvent evaporated to give a straw-colored liquid. The HCl salt(1.0 g) crystallized from CHCl₃ -EtOAc-ether, m.p. 165°-167° C.(Compound 17).

EXAMPLE 18(±)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo[2.2.2]-octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.05 g, 0.0043 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.24g, 0.0051 mol). After 1 h, 1-bromo-3,3-dimethylbutane (1.18 g, 0.007mol) was added and the reaction stirred overnight. The solvent wasevaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried and the solvent evaporated to give astraw-colored liquid. The HCl salt (0.41 g) crystallized from CHCl₃-EtOAc-ether, m.p. 189°-190° C. (Compound 18).

EXAMPLE 19(±)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicyclo-[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.0 g, 0.0041 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.1 g,0.0045 mol). After 1 h, 1-chloro-2-(2-thienylthio)ethane (1.1 g, 0.0062mol) was added and the reaction stirred overnight. The solvent wasevaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried, the solvent evaporated, and the residuepurified by flash chromatography (10% EtOH-1% NH₄ OH--CHCl₃) to give aliquid. The HCl salt (0.88 g) crystallized from ether, m.p. 179.5°-181°C. (Compound 19).

EXAMPLE 20(±)-3-(2,2,3,3,3-Pentafluoropropylthio)-4-(1-azabicyclo-[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (15 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.53 g,0.0022 mol). After 1 h, 1-methanesulfonoxy-2,2,3,3,3-pentafluoropropane(0.003 mol) was added and the reaction stirred overnight. The solventwas evaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried, the solvent evaporated, and the residuepurified by flash chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃) to give aliquid. The HCl salt (0.016 g) crystallized from ether, m.p. 138°-140°C. (Compound 20).

EXAMPLE 21(±)-3-(3-(2-Thienyl)propylthio)-4-(1-azabicyclo[2.2.2]-octyl-3-oxy-1,2,5-thiadiazole

A solution of the crude (compound 12) (0.6 g, 0.0024 mol) in DMF (15 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.6 g,0.0027 mol). After 1 h, 1-chloro-3-(2-thienyl)propane (0.6 g, 0.0036mol) was added and the reaction stirred overnight. The solvent wasevaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried, the solvent evaporated, and the residuepurified by flash chromatography (10% EtOH-1% NH₄ OH--CHCl₃) to give aliquid. The HCl salt (0.16 g) crystallized from EtOH-EtOAc, m.p.194°-196° C. (Compound 21).

EXAMPLE 22(±)-3-Butylthio-4-((1-azabicyclo[2.2.2]octan-3-yl)-methoxy)-1,2,5-thiadiazole

A solution of 3-hydroxymethyl-1-azabicyclo[2.2.2]octane (1.4 g, 0.01mol) in THF (30 mL) was treated with 1.6M n-butyllithium in hexane (6.5mL, 0.0104 mol). The mixture was cooled to 10° C., and3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (2.21 g, 0.0104 mol) in THF(10 mL) was added dropwise. Cooling was removed and the reaction stirredovernight. The reaction was treated with H₂ O, diluted with ether, andextracted with 1N HCl (25 mL). The acidic extracts were washed withether, made basic, and extracted with ether. The extracts were dried andthe solvent evaporated to give an orange liquid (1.82 g). The liquid wasdissolved in DMF (32 mL) and treated with freshly ground flaked Na₂S-9H₂ O (2.5 g, 0.0104 mol) in portions. After 55 min, the reaction wastreated with 1-iodobutane (2.6 g, 0.014 mol) and warmed to 44° C.overnight. The solvent was evaporated, the residue acidified with 1NHCl, and the mixture extracted with EtOAc-ether (1:1). The aqueousfraction was made basic and extracted with ether. The ether was dried,the solvent evaporated, and the residue purified by radialchromatography (5% EtOH-0.5% NH₄ OH--CHCl₃) to give a liquid. The HClsalt (0.84 g) crystallized from EtOAc-ether, m.p. 170°-171° C. (Compound22).

EXAMPLE 23(±)-exo-3-Pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazoleand (±)-Endo-3-pentylthio-4-(1-azabicyclo[3.2.1]-octyl-6-oxy)-1,2,5-thiadiazole

A solution of the endo/exo mixture of 1-azabicyclo[3.2.1]octan-6-ol(1.95 g, 0.0153 mol, ref. Sternbach, L. H.; Kaiser, S. J. Amer. Chem.Soc. 1952, 74, 2215-2218.) in THF (25 mL) was treated with 1.6Mn-butyllithium in hexane (9.6 mL, 0.0153 mol). When the mixture hadcooled to ambient temperature,3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (2.96 g, 0.014 mol) in THF(15 mL) was added dropwise and the reaction stirred overnight. Thereaction was treated with H₂ O, diluted with ether, and extracted with1N HCl (32 mL). The acidic extract was made basic, extracted with ether,the extracts dried, and the solvent evaporated to give an orange liquid(1.25 g). The liquid was dissolved in DMF (25 mL) and treated withfreshly ground flaked Na₂ S-9H₂ O (1.82 g, 0.0076 mol) in portions.After 40 min, 1-bromopentane (1.55 g, 0.0103 mol) was added and thereaction stirred overnight. The solvent was evaporated, the residueacidified, and the mixture extracted with ether. The aqueous fractionwas made basic, extracted with ether, the extracts dried, and thesolvent evaporated. The residue was purified by radial chromatography(2.5% EtOH-0.25% NH₄ OH-CHCl₃) to first elute the exo isomer as aliquid. The HCl salt (0.26 g), crystallized from EtOAc, m.p. 159°-160°C. (Compound 23). Further elution provided the endo isomer as a liquid.The HCl salt (0.23 g) crystallized from EtOAc, m.p. 190°-193° C.(Compound 24).

EXAMPLE 24(±)-endo-3-Butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazol

A solution of a mixture of (±)-endo and(±)-exo-1-azabicyclo[2.2.1]heptan3-ol (0.5 g, 0.0044 mol)(Ref. J, Org.Chem. 1969, 34, 3674-3676) in THF (20 mL) was cooled in an ice-waterbath and treated dropwise with 1.6M n-butyllithium in hexane (2.8 mL,0.0044 mol). Cooling was removed,3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.4 g, 0.0059 mol) wasadded, and the reaction heated to reflux for 6 h. The solvent wasevaporated, the residue acidified with 1N HCl, and the mixture extractedwith ether. The aqueous solution was made basic and extracted withEtOAc. The extracts were washed with H₂ O, dried, and the solventevaporated to give a clear oil. Radial chromatography (5% EtOH, 0.5% NH₄OH, CHCl₃) eluted the title compound as the more polar of the two UVactive spots. The HCl salt of the title compound (0.5 g) crystallizedfrom EtOAc with a quarter mole of H₂ O, m.p. 161.5°-163° C. (Compound25).

EXAMPLE 25(±)-Exo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole

Rechromatography of the mixed fractions from the isolation of (compound25) (5% EtOH, 0.5% NH₄ OH, CHCl₃) gave the less polar UV activematerial. The HCl salt (0.036 g) crystallized from EtOAc with a quartermole of water, m.p. 156°-157° C. (Compound 26).

EXAMPLE 26 (±)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole

A suspension of NaH (0.066 g, 0.0028 mol) in THF (25 mL) was treatedwith 1-t-butylcarbamoyl-3-hydroxypyrrolidine (Ref. Syn. Commun. 15,587.) (0.5 g, 0.0027 mol) and the reaction warmed to 50° C. for 30 min.After cooling to ambient temperature,3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (0.55 g, 0.0027 mol) inTHF (5 mL) was added and the reaction heated to reflux for 2.5 h. Thesolvent was evaporated, the residue treated with ice-water, and themixture extracted with ether. The extracts were washed with brine,dried, and the solvent evaporated. The residue was dissolved in ether(50 mL) and treated with a slow stream of HCl for 5 min. After stirringovernight, the reaction was extracted with cold water. The aqueous waswashed with ether, made basic, and extracted with EtOAc. The extractswere washed with brine, dried, and the solvent evaporated to give aclear oil. The HCl salt (0.42 g) crystallized from EtOAc, m.p. 127°-128°C. (Compound 27).

EXAMPLE 27(±)-3-Butyloxy-4-(1-methyl-3-pyrrolidinyloxy)-1,2,5-thiadiazole

A solution of 1-methyl-3-pyrrolidinol (0.6 g, 0.0059 mol) in THF (20 mL)was treated with 1.6M n-butyllithium in hexane (3.1 mL), 0.005 mol). Tothe solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole(1.0 g, 0.0042 mol) and the reaction heated to reflux overnight. Thesolvent was evaporated, the residue acidified with cold 1N HCl, and themixture extracted with ether. The aqueous fraction was made basic,extracted with EtOAc, and the extracts washed with water. The extractswere dried and the solvent evaporated to give a liquid. The HCl salt(0.7 g) crystallized from EtOAc, m.p. 157°-158° C. (Compound 28).

EXAMPLE 28 (±)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole

A solution of 3-hydroxy-l-methylpiperidine (1.12 g, 0.0095 mol) in THF(25 mL) was treated with 1.6M n-butyllithium in hexane (5.9 mL, 0.0095mol). The mixture was cooled to 8° C. and treated dropwise with3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF(20 mL). The cooling was removed and the reaction stirred overnight. Themixture was treated with H₂ O, acidified with 1N HCl and diluted withether. The aqueous fraction was washed with ether, made basic, andextracted with ether. The extracts dried and solvent evaporated to givea brown liquid (1.95 g). The liquid was dissolved in DMF (38 mL) andtreated with freshly ground flaked Na₂ S-9H₂ O (2.98 g, 0.0124 mol) inportions. After 1 h, the mixture was treated with 1-iodobutane (3.1 g,0.0169 mol) and stirred 64 h. The solvent was evaporated, the residueacidified with 1N HCl, and the mixture extracted with ether. The aqueoussolution was made basic and extracted with ether. The extracts weredried and the solvent evaporated to give an orange liquid. Purificationby radial chromatography (2.5% EtOH-0.25% NH₄ OH--CHCl₃) gave a liquidwhose HCl salt (1.4 g) crystallized from CHCl₃ -EtOAc-ether, m.p.141°-142° C. (Compound 29).

EXAMPLE 29 3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole

A solution of 4-hydroxy-1-methylpiperidine (1.12 g, 0.0095 mol) in THF(25 mL) was treated with 1.6M n-butyllithium in hexane (5.9 mL, 0.0095mol). The mixture was cooled to 8° C. and treated dropwise with3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.83 g, 0.0086 mol) in THF(20 mL). The cooling was removed and the reaction stirred overnight. Themixture was treated with H₂ O, acidified with 1N HCl, and diluted withether. The aqueous fraction was washed with ether, made basic, andextracted with ether. The extracts dried and solvent evaporated to givea brown liquid (1.52 g). The liquid was dissolved in DMF (30 mL) andtreated with freshly ground flaked Na₂ S-9H₂ O (2.32 g, 0.0097 mol) inportions. After 50 min, the mixture was treated with 1-iodobutane (2.4g, 0.013 mol) and stirred for 63 h. The solvent was evaporated, theresidue acidified with dilute HCl, and the mixture extracted with ether.The aqueous fraction was made basic and extracted with ether. Theextracts were dried and the solvent evaporated to give 1.3 g liquid. TheHCl salt (1.3 g) crystallized from EtOAc-ether, m.p. 140°-142° C.(Compound 30).

EXAMPLE 30(S)-3-Butyloxy-4-(1-methyl-2-pyrrolidinylmethyloxy)-1,2,5-thiadiazole

A solution of (S)-1-methyl-2-pyrrolidinemethanol (0.86, 0.0075 mol) inTHF (20 mL) was treated with 1.6M n-butyllithium in hexane (4.7 mL,0.0075 mol). To the solution was added3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.2 g, 0.005 mol) andthe reaction heated to reflux for 6.5 h. The solvent was evaporated, theresidue acidified with cold 1N HCl, and the mixture extracted withether. The aqueous was made basic and extracted with EtOAc. The extractswere washed with water, dried, and the solvent evaporated to give aliquid. The HCl salt (0.72 g) crystallized from EtOAc, m.p. 115°-116° C.(Compound 31).

EXAMPLE 31 (S)-3-Butyloxy-4-(2-pyrrolidinylmethyloxy)-1,2,5-thiadiazole

A solution of (S)-1-butyloxycarbonyl-2-pyrrolidinemethanol (1.21, 0.006mol) in THF (5 mL) was added to a suspension of 60% NaH in oil (0.24 g,0.006 mol) in THF (30 mL). After 1 h, the mixture was heated to gentlereflux for 1 h. To the solution was added3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1 g, 0.0042 mol) and thereaction heated to reflux overnight. The solvent was evaporated, theresidue treated with cold H₂ O, and the mixture extracted with EtOAc.The extracts were dried and treated with a stream of dry HCl for 3 min.After another hour, the solvent was evaporated, the residue treated withcold H₂ O, and the mixture extracted with ether. The aqueous fractionwas made basic and extracted with EtOAc. The extracts were washed withwater, dried, and the solvent evaporated to give a liquid. The HCl salt(0.72 g) crystallized from EtOAc, m.p. 99°-100° C. (Compound 32).

EXAMPLE 32 3-Butyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole

A solution of 2-dimethylaminoethanol (0.67 g, 0.0075 mol) in THF (20 mL)was treated with 1.6M n-butyllithium in hexane (4.7 mL, 0.0075 mol). Tothe solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole(1.2 g, 0.005 mol) and the reaction heated to reflux for 6 h. Thesolvent was evaporated, the residue acidified with cold 1N HCl, and themixture extracted with ether. The aqueous was made basic and extractedwith EtOAc. The extracts were washed with water, dried, and the solventevaporated to give a clear oil. The HCl salt (0.94 g) recrystallizedfrom EtOAc to give a white solid, m.p. 97°-98° C. (Compound 33).

EXAMPLE 33 3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole

A solution of 2-diethylaminoethanol (1.11 g, 0.0095 mol) in THF (25 mL)was treated with 1.6M n-butyllithium in hexane (5.9 mL, 0.0095 mol). Themixture was cooled to 8° C. and treated dropwise with3-chloro-4-ethylsulfonyl-1,2,5thiadiazole (1.83 g, 0.0086 mol) in THF(20 mL). The cooling was removed and the reaction stirred overnight. Themixture was treated with H₂ O, acidified with 1N HCl, and diluted withether. The aqueous fraction was washed with ether, made basic, andextracted with ether. The extracts dried and solvent evaporated to givea brown liquid (1.6 g). The liquid was dissolved in DMF (30 mL) andtreated with freshly ground flaked Na₂ S-9H₂ O (2.43 g, 0.010 mol) inportions. After 50 min, the mixture was treated with 1-iodobutane (2.52g, 0.0137 mol) and stirred for 46 h. The solvent was evaporated, theresidue acidified with dilute HCl, and the mixture extracted with ether.The aqueous fraction was made basic and extracted with ether. Theextracts were dried, the solvent evaporated, and the residue purified byradial chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃) to give a liquid. TheHCl salt (1.15 g) crystallized from EtOAc-ether, m.p. 95°-97° C.(Compound 34).

EXAMPLE 34 3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazoleiodide

A solution of (compound 33) (from 0.5 g, 0.0018 mol of the HCl salt) inEtOAc (30 mL) was treated with CH₃ I (0.3 mL) and stirred overnight. Theprecipitant was collected, washed with EtOAc, and dried to give a whitesolid (0.64 g), m.p. 137°-138° C. (Compound 35).

EXAMPLE 35 3-Butyloxy-4-(2-(dimethylamino)ethylthio)-1,2,5-thiadiazole

A suspension of 2-dimethylaminoethanthiol hydrochloride (0.57 g, 0.004mol) in THF (25 mL) was treated with 1.6M n-butyllithium in hexane (5mL, 0.008 mol). To the solution was added3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (0.71 g, 0.003 mol) andthe reaction heated to reflux for 2 h followed by stirring at ambienttemperature overnight. The solvent was evaporated, the residue acidifiedwith cold 1N HCl, and the mixture extracted with ether. The aqueous wasmade basic and extracted with ether. The extracts were washed withwater, dried, and the solvent evaporated. The residue was purified byradial chromatography (5% EtOH-0.5% NH₄ OH-CHCl₃) to give a tan liquid.The HCl salt (0.22 g) recrystallized from EtOAc to give a white solid,m.p. 108°-109° C.-(Compound 36).

EXAMPLE 36 3-Chloro-4-(1-propylthio)-1,2,5-thiadiazole

Cyanogen (34 g, 0.65 mol) was bubbled into ether (250 mL) maintained at-10° C. To the solution was added dropwise diethylamine (3 mL) followedby dropwise addition of 1-propanethiol (57 mL, 0.63 mol) in ether (25mL) at such a rate that the temperature did not exceed -5° C. After 5 h,cooling was removed and the reaction stirred overnight. Ether wasdistilled from the reaction until the pot temperature reached 50° C. Thereaction was cooled to ambient and added dropwise to a solution ofsulfur monochloride (125 mL, 1.56 mol) in DMF (125 mL) that was cooledin an ice-water bath. Cooling was removed and the reaction allowed toexotherm to 35° C., recooled to below 30° C., then stirred overnight.The reaction was cooled in EtOH-ice and the excess sulfur monochloridecarefully destroyed by dropwise addition of H₂ O (200 mL) such that thetemperature did not exceed 30° C. The mixture was extracted with hexane,the extracts washed with brine, dried, and the solvent evaporated. Theresidue was distilled at 1.5 mm Hg to give a yellow liquid (98.6 g),b.p. 84°-94° C. (Compound 37).

EXAMPLE 37(R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of (R)-1-azabicyclo[2.2.2]octan-3-ol (3.0 g, 0.0236 mol) inTHF (40 mL) was cooled to 10° C. as 1.6M n-butyllithium in hexane (15mL, 0.024 mol) was added dropwise. The resulting mixture was treatedwith 3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (5.01 g, 0.0236 mol) inTHF (5 mL) and stirred for 22 h. The reaction was treated with H₂ O (10mL), ether (170 mL) and extracted with 1N HCl (35 mL). The aqueousfraction was washed with ether, made basic, and extracted with ether.The extracts were dried and the solvent evaporated to give an oil (2.35g). The oil was dissolved in DMF (35 mL), treated portionwise withfreshly ground flaked Na₂ S-9H₂ O (2.53 g, 0.0105 mol), and heated (40°C.). After 1.25 h, 1-bromopentane (2.18 g, 0.0145 mol) was added and thereaction stirred overnight at 38° C. The solvent was evaporated, theresidue was acidified with 1N HCl, and the mixture extracted with ether.The aqueous was made basic and extracted with ether. The extracts weredried and the solvent evaporated to give a straw-colored liquid that waspurified by radial chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃), The HClsalt (1.68 g) crystallized from CHCl₃ -EtOAc, m.p. 195°-196° C., [α]_(D)=-24.6° (EtOH). (Compound 38).

EXAMPLE 38(±)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.65 g, 0.0067 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.83g, 0.0076 mol). After 1 h, 1-bromo-4-methylpentane (1.73 g, 0.0105 mol)was added and the reaction stirred three days at 40° C. The solvent wasevaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried and the solvent evaporated to give astraw-colored liquid that was purified by radial chromatography (5%EtOH-0.5% NH₄ OH-CHCl₃). The HCl salt (0.74 g) crystallized from CHCl₃-EtOAc-ether, m.p. 183°-185° C. (Compound 39).

EXAMPLE 39(±)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (0.9 g, 0.0037 mol) in DMF (25 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.97 g,0.004 mol). After 1 h, 1-bromo-3-phenylpropane (1.11 g, 0.056 mol) wasadded and the reaction stirred 17 h at 50° C. The solvent wasevaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried and the solvent evaporated to give astraw-colored liquid that was purified by radial chromatography (2.5%EtOH-0.25% NH₄ OH-CHCl₃). The HCl salt (0.42 g) crystallized from CHCl₃-EtOAc-ether, m.p. 210°-212° C. (Compound 40).

EXAMPLE 40(±)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68g, 0.007 mol). After 1 h, 4-cyanobenzyl bromide (1.85 g, 0.094 mol) wasadded and the reaction stirred 22 h. The solvent was evaporated, theresidue was acidified with 1N HCl, and the mixture extracted with ether.The aqueous was made basic and extracted with ether. The extracts weredried and the solvent evaporated to give a straw-colored liquid that waspurified by radial chromatography (5% EtOH-0.5% NH₄ OH-CHCl₃). The HClsalt (0.12 g) crystallized from CHCl₃ -EtOAc-ether, m.p. 211°-213° C.(Compound 41).

EXAMPLE 41(±)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68g, 0.007 mol). After 1 h, 4-fluorobenzyl chloride (1.37 g, 0.094 mol)was added and the reaction stirred 22 h. The solvent was evaporated, theresidue was acidified with 1N HCl, and the mixture extracted with ether.The aqueous was made basic and extracted with ether. The extracts weredried and the solvent evaporated to give a straw-colored liquid that waspurified by radial chromatography (5% EtOH-0.5% NH₄ OH-CHCl₃). The HClsalt (0.89 g) crystallized from MeOH-EtOAc-ether, m.p. 236°-237° C.(Compound 42).

EXAMPLE 42(±)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68g, 0.007 mol). After 1 h, the reaction was cooled to -30° C. and treatedwith dropwise with 1-bromo-2-phenylethane (1.75 g, 0.095 mol) in DMF (22mL). The cooling was removed after 1 h and the reaction stirred 22 h.The solvent was evaporated, the residue was acidified with 1N HCl, andthe mixture extracted with ether. The aqueous was made basic andextracted with ether. The extracts were dried and the solvent evaporatedto give a straw-colored liquid that was purified by radialchromatography (5% EtOH-0.5% NH₄ OH-CHCl₃). The HCl salt (0.53 g)crystallized from MeOH-EtOc-ether, m.p. 181°-183° C. (Compound 43).

EXAMPLE 43(±)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (1.15 g, 0.0047 mol) in DMF (25mL) was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68g, 0.007 mol). After 1 h, the reaction was cooled to -50° C. and treatedwith dropwise with 1-bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) in DMF(22 mL). The cooling was removed after 1 h and the reaction stirred 22h. Another solution of bromo-2-phenyloxyethane (1.90 g, 0.0095 mol) inDMF (5 mL) was added in two portions with cooling to -30° C. After 2 h,the solvent was evaporated, the residue was acidified with 1N HCl, andthe mixture extracted with ether. The aqueous was made basic andextracted with CHCl₃. The extracts were dried and the solvent evaporatedto give a straw-colored liquid that was purified by radialchromatography (5% EtOH-0.5% NH₄ OH--CHCl₃). The HCl salt (1.29 g)crystallized from MeOH-EtOAc-ether, m.p. 193°-194° C. (Compound 44).

EXAMPLE 44endo-3-Butyloxy-4-(N-methyl-8-azabicyclo[3.2.1]octyl-3-oxy-1,2,5-thiadiazole

A solution of tropine (1.36 g, 0.0094 mol) in THF (25 mL) was treateddropwise with 1.6M n-butyllithium in hexane (5.9 mL, 0.00095 mol). Tothis solution was added 3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole(2.04 g, 0.0086 mol) in THF (25 mL) and the reaction heated to 40° C.for 19 h. The solution was treated with H₂ O (40 mL), 5N HCl (5.5 mL),and ether (150 mL), the aqueous layer separated and made basic. Theaqueous solution was extracted with ether, the extracts dried, and thesolvent evaporated to give a clear oil. The oil was purified by radialchromatography (5% EtOH-0.5% NH₄ OH--CHCl₃) and the HCl salt (1.49 g)crystallized from CHCl₃ -EtOAc-ether, m.p. 168°-169° C. (Compound 45).

EXAMPLE 45(±)-exo-3-Butyloxy-4-(6-(N-methyl-8-azabicyclo[3.2.1]octan-3-onoxy))-1,2,5-thiadiazole

A suspension of NaH (0.11 g, 0.00275 mol) in THF (25 mL) was treatedwith (±)-exo-6-hydroxytropinone (1.36 g, 0.0094 mol) and the reactionheated to 50° C. for 1 h. To this solution was added3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (0.55 g, 0.0027 mol) andthe reaction heated to reflux for 2 h. The solvent was evaporated, theresidue suspended in ice-water, acidified, and the mixture extractedwith ether. The aqueous layer was made basic, was extracted with ether,the extracts washed with brine, dried, and the solvent evaporated togive a clear oil. The oil was purified by radial chromatography (2.5%EtOH-0.25% NH₄ OH--CHCl₃) and the HCl salt (0.325 g) crystallized fromEtOAc, m.p. 178°-179° C. (Compound 46).

EXAMPLE 46(±)-exo-3-Chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5thiadiazoleand(±)-endo-3-Chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of the endo/exo mixture of 1-azabicyclo[3.2.1]octan-6-ol (13g, 0.102 mol, ref. Sternbach, L. H.; Kaiser, S. J. Amer. Chem. Soc.1952, 74, 2215-2218), triethylamine (0.3 mL), and CHCl₃ (100 mL) wascooled to 3° C. and cyanogen (7.7 g, 0.148 mol) bubbled into thesolution. After 1 h, the cooling was removed, the reaction stirredanother 3 h, and the solvent evaporated. The residue was dissolved inDMF (30 mL) and added dropwise to a solution of S₂ Cl₂ (47.3 g, 0.35mol) in DMF (30 mL) that was cooled in an ice-water bath. Cooling wasremoved, the reaction stirred overnight, and, after further cooling, theexcess S₂ Cl₂ carefully destroyed with H₂ O. The mixture was dilutedwith H₂ O (200 mL), the aqueous solution decanted, and the sulfurresidue triturated with H₂ O. The combined aqueous solutions wereevaporated to a small volume (150 mL) and extracted with hexane. Theaqueous solution was cooled, made basic with 50% NaOH, and extractedwith CHCl₃. The extracts were dried, the solvent thoroughly evaporated,the residue suspended in ether and filtered. Evaporation of the solventgave a brown liquid (12.76 g), a 0.8 g sample of which was purified byradial chromatography (10% EtOH-1% NH₄ OH--CHCl₃). The exo isomer elutedfirst and was converted to an HCl salt (0.1 g) that crystallized fromacetone, m.p. 226° C., dec. (compound 47). Further elution provided theendo isomer that crystallized as an HCl salt (0.2 g) from 2-propanol,m.p. 199.5°-201° C. (Compound 48).

EXAMPLE 47(±)-endo-3-(4-Cyanobenzylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of the crude mixture of (compound 47) and (compound 48) (2.3g, 0.0094 mol) in DMF (34 mL) was treated portionwise with freshlyground flaked Na₂ S-9H₂ O (3.36 g, 0.014 mol). After 2 h, the reactionwas cooled to -30° C. and treated with dropwise with 4-cyanobenzylbromide (3.7 g, 0.0189 mol) in DMF (34 mL). The cooling was removed andafter 1.5 h, the reaction was treated with 5N NaOH (4 mL). The solventswere evaporated, the residue dissolved in a mixture of CHCl₃ and H₂ O,the CHCl₃ extract separated, and washed with H₂ O. The organic extractswere dried, the solvent evaporated, and the residue purified by radialchromatography (5% EtOH-0.5% NH₄ OH-EtOAc) to give the endo isomer. TheHCl salt (0.31 g) crystallized from MeOH-EtOAc-ether, m.p. 250°-251° C.(Compound 49).

EXAMPLE 48 3-Butyloxy-4-(3-azetidinyloxy)-1,2,5-thiadiazole

A suspension of NaH (0.24 g, 0.006 mol) in THF (30 mL) was treated with1-t-butylcarbamoyl-3-hydroxyazetidine (1.1 g, 0.006 mol), the reactionstirred 1 h, followed by addition of3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol) inTHF (5 mL). The reaction was heated to reflux for 4 h, the solventevaporated, the residue treated with ice-water, and the mixtureextracted with EtOAc. The extracts were dried and treated with a slowstream of HCl for 3 min. After 0.5 h, the solvent was evaporated, theresidue treated with ice-water, and the solution extracted with ether.The aqueous phase was made basic, extracted with EtOAc, the extractswashed with brine, dried, and the solvent evaporated to give a clearoil. The HCl salt (0.77 g) crystallized from 2-propanol, m.p.167°-168.5° C. (Compound 50).

EXAMPLE 49 3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole

A suspension of NaH (0.24 g, 0.006 mol) in THF (30 mL) was treated with1-t-butylcarbamoyl-3-hydroxyazetidine (1.6 g, 0.0092 mol), and thereaction stirred 1 h. After cooling to 8° C.,3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.96 g, 0.0092 mol) in THF(5 mL) was added, the reaction stirred 30 min, cooling removed for 30min, and the reaction heated to 35° C. for 45 min. Heating was removed,the reaction stirred overnight, and the solvent evaporated. The residuewas suspended in cold water, the mixture extracted with EtOAc, theextracts washed with brine, dried, and the solvent evaporated to give atan liquid, (2.98 g). A DMF (30 mL) solution of the liquid was treatedwith freshly ground flaked Na₂ S-9H₂ O (3.3 g, 0.0138 mol). After 1 h,1-iodobutane (2.1 mL) was added, the reaction stirred 2 h, diluted withcold water, and extracted with ether. The ether was dried, the solventevaporated, the residue dissolved in EtOAc, and the solution treatedwith a stream of dry HCl for 5 min. After 1 h, the reaction was treatedwith icewater and the organic solvent evaporated. The aqueous solutionwas extracted with ether, made basic, and extracted with EtOAc. TheEtOAc extracts were dried and the solvent evaporated to give a tanliquid that was purified by radial chromatography (10% EtOH-1% NH₄OH--CHCl₃). The HCl salt (0.41 g) crystallized from EtOAc, m.p.138°-139° C. (Compound 51).

EXAMPLE 50(±)-trans-3-Butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole

A suspension of NaH (0.25 g, 0.006 mol) in THF (30 mL) was treated with(±)-trans-dimethylaminocyclopentanol (0.8 g, 0.006 mol), the reactionheated to reflux 1 h, followed by addition of3-butyloxy-4-methanesulfonyl-1,2,5-thiadiazole (1.0 g, 0.0042 mol), andthe heating continued overnight. The solvent was evaporated, the residuesuspended in cold water, and the mixture acidified. The solution wasextracted with ether, made basic, and extracted with EtOAc. The EtOAcextracts were washed with brine, dried, the solvent evaporated, and theresidue purified by radial chromatography (10% EtOH-1% NH₄ OH--CHCl₃).The HCl salt (0.98 g) crystallized from EtOAc, m.p. 148°-149° C.(Compound 52).

EXAMPLE 51 (±)-3-Butylthio-4-(3-pyrrolidnyloxy)-1,2,5-thiadiazole

A suspension of NaH (0.22 g, 0.009 mol) in THF (30 mL) was treated with(±)-1-t-butylcarbamoyl-3-hydroxypyrrolidine (1.73 g, 0.0092 mol), andthe reaction heated to reflux for 35 min. After cooling to 10° C.,3-chloro-4-ethylsulfonyl-1,2,5-thiadiazole (1.96 g, 0.0092 mol) in THF(5 mL) was added, cooling was removed, and the reaction heated to 35° C.for 16 h. The reaction was diluted with H₂ O, ether added, and the etherextract separated. The ether extract was washed with H₂ O, dried, andthe solvent evaporated to give a tan liquid, (3.05 g). A DMF (42 mL)solution of the liquid was treated with freshly ground flaked Na₂ S-9H₂O (3.3 g, 0.0138 mol). After 1 h, 1-iodobutane (3.42 g, 0.0186 mol) wasadded, and the reaction stirred at 40° C. for 16 h. The solvent wasevaporated, the residue diluted with cold water, and the mixtureextracted with ether. The ether was dried, the solvent evaporated, theresidue dissolved in ether, and the solution treated with a stream ofdry HCl for 5 min. After 66 h, the reaction was treated with ice-waterand the organic solvent evaporated. The aqueous solution was extractedwith ether, made basic, and extracted with ether. The ether extractswere dried and the solvent evaporated to give a tan liquid that waspurified by radial chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃). The HClsalt (0.67 g) crystallized from EtOAc, m.p. 99°-100.5° C. (Compound 53).

EXAMPLE 52 1-Chloro-2-(2-thio-5-trifluoromethylthienyl)ethane

A solution of 2-trifluoromethylthiophene (1.2 g, 0.0105 mol, J. FluorineChem. 1990, 46, 445-459) in THF (10 mL) was cooled to -40° C. as 1.6Mn-butyllithium in hexane (6.5 mL, 0.0103 mol) was added dropwise. After2 h, the reaction was cooled to -78° C. and S (0.32 g, 0.01 mol) wasadded and the reaction stirred 2 h. Cooling was removed and whentemperature reached 0° C., the reaction was quenched with H₂ O anddilute NaOH. The mixture was extracted with ether, the aqueous phaseacidified, and the mixture extracted with ether. The final etherextracts were dried and the solvent evaporated to give 2 g of material.This was added to a mixture of KOH (0.6 g, 0.011 mol), N(butyl)₄ HSO₄(0.3 g, 0.001 mol), and 1-bromo-2-chloroethane (1.4 g, 0.01 mol) in THF(20 mL) and the reaction stirred at ambient overnight. The mixture waspoured into H₂ O, extracted with CH₂ Cl₂, the extracts dried, and thesolvent evaporated. The residue was purified by flash chromatography (5%EtOAc-hexane) to give a liquid (0.42 g). (Compound 54).

EXAMPLE 53(±)-3-(2-(2-Thio-5-trifluoromethylthienyl)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (0.37 g, 0.0015 mol) in DMF (8 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.41 g,0.0017 mol). After 1 h, 1-chloro-2-(2-thio-5-trifluoromethylthienyl)ethane (0.42 g, 0.0017 mol) was added and the reaction stirredovernight. The solvent was evaporated, the residue was acidified with 1NHCl, and the mixture extracted with ether. The aqueous was made basicand extracted with ether. The extracts were dried, the solventevaporated, and the residue purified by radial chromatography (10%EtOH-1% NH₄ OH--CHCl₃) to give a liquid. The oxalate salt (0.107 g)crystallized from 2-propanol, m.p. 65°-69° C. (Compound 55).

EXAMPLE 54 2-(5-(2-Thienyl)thioohene) thiol

A solution of 2-(2-thienyl)thiophene (10 g, 0.0602 mol) in THF (50 mL)was cooled to -40° C. as 1.6M n-butyllithium in hexane (37.2 mL, 0.0595mol) was added dropwise. After 2 h, the reaction was cooled to -78° C.and S (1.8 g, 0.0575 mol) was added and the reaction stirred 2 h.Cooling was removed and when temperature reached 0° C., the reaction wasquenched with H₂ O and dilute NaOH. The mixture was extracted withether, the aqueous phase acidified, and the mixture extracted withether. The final ether extracts were dried and the solvent evaporated togive 9.9 g of material. (Compound 56).

EXAMPLE 55 (±)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5 -thiadiazole

A mixture of 2-(5-(2-thienyl)thiophene)thiol (1.2 g, 0.0061 mol),potassium t-butoxide (0.5 g, 0.0045 mol), and a trace of 18-Crown-6 inTHF (90 mL) was stirred for 1.5 h. To the solution was added (compound12) (1.0 g, 0.0041 mol) and the reaction heated to reflux overnight. Thereaction was poured into H₂ O, extracted with ether, the extracts dried,and the solvent evaporated. The residue was purified by flashchromatography (5% EtOH-0.5% NH₄ OH-CHCl₃) and the oxalate salt (0.41 g)crystallized from acetone, m.p. 215° C., dec. (Compound 57).

EXAMPLE 56 1-Chloro-2-(2-(5-(2-thienyl)thienyl)thio)ethane

Crude 2-(5-(2-thienyl)thiophene)thiol (3 g, 0.0152 mol) was added to amixture of KOH (0.93 g, 0.0166 mol), N(butyl)₄ HSO₄ (0.51 g, 0.0015mol), and 1-bromo-2-chloroethane (2.2 g, 0.0152 mol) in THF (100 mL) andthe reaction stirred at ambient overnight. The mixture was poured intoH₂ O, extracted with CH₂ Cl₂, the extracts dried, and the solventevaporated to give the desired product (3.5 g). (Compound 58).

EXAMPLE 57(±)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (10 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.55 g,0.0023 mol). After 1 h, 1-chloro-2-(2-(5-(2-thienyl)thienyl)thio)ethane(0.6 g, 0.0023 mol) was added and the reaction stirred overnight. Thesolvent was evaporated, the residue was acidified with 1N HCl, and themixture extracted with ether. The aqueous was made basic and extractedwith ether. The extracts were dried, the solvent evaporated, and theresidue purified by flash chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃) togive a liquid. The oxalate salt (0.43 g) crystallized from acetone, m.p.102°-105° C. (Compound 59).

EXAMPLE 58(±)-3-(2-Thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A mixture of 2-thiophenethiol (0.42 g, 0.0036 mol) and K₂ CO₃ (0.59 g,0.0043 mol), in DMF (20 mL) was heated at 60° C. for 3 h. To thesolution was added (compound 12) (0.89 g, 0.0036 mol) and the reactionheated overnight. The reaction was poured into 1N HCl (50 mL), extractedwith ether, the aqueous phase made basic, and the mixture extracted withEtOAc. The EtOAc extracts were dried, the solvent evaporated, and theresidue purified by flash chromatography (5% EtOH-0.5% NH₄ OH--CHCl₃).The oxalate salt (0.095 g) crystallized from acetone, m.p. 133°-136° C.(Compound 60).

EXAMPLE 59(±)-3-(3-N-(2-Thiazolidonyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)1,2,5-thiadiazole

A solution of the crude (compound 12) (0.5 g, 0.002 mol) in DMF (10 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (0.55 g,0.0023 mol). After 1 h, 1-chloro-3-N-(2-thiazolidone) propane (0.41 g,0.0023 mol) was added and the reaction stirred overnight. The solventwas evaporated, the residue was acidified with 1N HCl, and the mixtureextracted with ether. The aqueous was made basic and extracted withether. The extracts were dried, the solvent evaporated, and the residuepurified by radial chromatography (10% EtOH-1% NH₄ OH--CHCl₃) to give aliquid. The oxalate salt (0.148 g) crystallized from acetone-ether, m.p.70°-75° C. (Compound 61).

EXAMPLE 60(±)exo-Methyl-7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate

A solution of 2.1 g (8.4 mmol) methyl7-acetoxy-7-cyano-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (J. Org.Chem. 1989, 54, 2893) in 25 mL ethanol and 5 mL H₂ O was cooled in anice bath. To this mixture was added 2.4 g (42 mmol) KOH followed by 0.65g (17 mmol) NaBH₄. After 15 min. the ice bath was removed and thereaction was stirred for 16 h. The reaction was quenched by addition of25 mL H₂ O and then concentrated under vacuum. To the residue was added25 mL H₂ O and the mixture was extracted three times with 50 mL portionsof EtOAc. The combined extracts were dried over NaCl/Na₂ SO₄ andevaporated under vacuum. The residue was chromatographed (25%EtOAc/hexane) on silica gel to give 1.47 g of exo methyl7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 135 mg of endomethyl 7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate. (Compound62).

EXAMPLE 61(±)exo-Methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxolate

A solution of 1.47 g (8 mmol) exo methyl7-hydroxy-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate and 0.15 g 5% Pd/Cin 50 mL methanol was hydrogenated at 50 psi on a Parr shaker for 5 h atroom temperature. Removal of the catalyst by filtration followed byevaporation under vacuum afforded 1.43 g. (Compound 63).

EXAMPLE 62 (±)3-Butylthio-4-(exo-2-methoxycarbonyl-2-azabicyclo[2.2.2]oct-6-yloxy)1,2,5-thiadiazole

To a solution of 1.3 g (7.1 mmol) exo methyl6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate and 0.80 g (7.1 mmol)potassium t-butoxide in 20 mL of THF was added 1.5 9 (7.1 mmol)3-chloro-4-butylthio-1,2,5-thiadiazole. After stirring the mixture atroom temperature for 20 h, 50 mL of brine was added and the solution wasextracted five times with 50 mL portions of EtOAc. The combined extractswere dried over NaCl/Na₂ SO₄ and evaporated under vacuum. Chromatographyover silica gel (25% EtOAc/hexane) afforded 1.42 g. (Compound 64).

EXAMPLE 63(±)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole

Trimethylsilyliodide 0.70 mL (4.9 mmol) was added to a solution of3-butylthio-4-(exo-2-methoxycarbonyl-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazolein 10 mL of CH₂ Cl₂. After stirring for 5 h at room temperature, thesolution was evaporated under vacuum. 10 mL of saturated NaHCO₃ wasadded and the solution was extracted three times with 20 mL portions ofEtOAc. The combined extracts were dried over NaCl/Na₂ SO₄ and evaporatedunder vacuum. The residue was chromatographed over silica gel (10% EtOH,1% NH₄ OH--CHCl₃) and the resulting oil converted to its oxalate salt.Recrystallization from EtOH/EtOAc afforded 789 mg (mp. 148°-150° C.).(Compound 65).

EXAMPLE 64 3-Amino-4-butylthio-1,2,5-thiadiazole

A 1.04 g sample of 3-chloro-4-butylthio-1,2,5-thiadiazole was dissolvedin 20 mL of THF and added to a 50 mL reaction vessel. The mixture wascooled to 0° C. A 10 mL sample of sodium bis(trimethylsilyl)amide in THF(1.0M) was added dropwise to the reaction vessel. The mixture wasstirred at 0° C. The reaction was quenched using 50 mL water upondesired completion of reaction. The pH of the mixture was adjusted to2.0 using HCl. The mixture was stirred for 15 min. and then adjusted topH=11 using NaOH. The mixture was extracted using ether. The organiclayers were combined, dried, and filtered. The filtrate was concentratedto dryness. The resulting product was purified using columnchromatography. Yield: 1.07 g (65%). TheN,N-bis(trimethylsilyl)-3-amino-4-butylthio-1,2,5-thiadiazole wassuspended in 3N HCl and heated to about 50° C. The mixture was stirredfor 3 h. The pH was adjusted to 11 using NaOH. The mixture was extractedusing t-butylmethyl ester. The organics were combined, dried, filteredand concentrated to dryness. Yield: 0.43 g (45%). (Compound 66). Theprocess substantially as described was repeated to yield 82% of thedesired 3-amino-4-butylthio-1,2,5-thiadiazole.

EXAMPLE 65 3-Bromo-4-butylthio-1,2,5-thiadiazole

A 0.42 g sample of cupric bromide, 0.28 isoamyl nitrite and 6 mLacetonitrile were added to a 25 mL reaction vessel. The mixture waswarmed to 65° C. The acetonitrile mixture was added to a 4 mLacetonitrile solution containing 0.30 g4-amino-3-butylthio-1,2,5-thiadiazole. The mixture was stirred for 30min. at 65°. The mixture was cooled to room temperature and quenchedwith 50 mL of 1N HCl. The organic layers were combined, dried, filteredand concentrated to dryness. Yield: 0.38 g (94%). The resulting materialwas purified using column chromatography to yield 0.30 g (73%) ofmaterial. (Compound 67).

The process substantially as described above was completed usingcopper(I) iodide (0.61 9) to provide3-iodo-4-butylthio-1,2,5-thiadiazole. Yield: 0.23 g (48%). (Compound68).

EXAMPLE 66(±)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole

A solution of potassium t-butoxide (1.6g, 0.0143 mol) in THF (12 mL) wastreated with 2,2,3,3,4,4,4-heptafluorobutanol (2 mL, 0.016 mol). After 5min, Compound 12 (0.75 g, 0.003 mol) was added, the reaction stirred 2 hfollowed by heating to reflux for 1.5 h. After stirring at ambienttemperature overnight and heating to reflux for another 1.5 h, thesolvent was evaporated, the residue suspended in H₂ O, and the mixtureextracted with EtOAc. The extracts were dried, the solvent evaporated,and the residue purified by radial chromatography (20% EtOH-2% NH₄OH--CHCl₃) to give an oil. The hydrochloride salt crystallized fromEtOAc with a half mole of H₂ O as a flocculent white solid (0.43 g),m.p. 168.5°-169.5° C. (Compound 69).

EXAMPLE 67(±)3-(1-Butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole

A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (12 mL)was treated with endo-1-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005 mol).After 5 min, 3-chloro-4-(1-butylthio)-1,2,5-thiadiazole (1.2 g, 0.0057mol) was added. After stirring overnight, the solvent was evaporated,the residue diluted with H₂ O, acidified, and extracted with ether. Theaqueous phase was made basic and extracted with EtOAc, the extractsdried, washed with brine, dried, and the solvent evaporated. The residuewas purified by radial chromatography (20% EtOH-2% NH₄ OH--CHCl₃). TheHCl salt crystallized from EtOAc to give a white solid (0.68 g), m.p.201°-202° C. dec. (Compound 70).

EXAMPLE 68(±)3-(3-Phenylpropylthio)-4-[endo-6-(1-azabicyclo[3.2.1]¢octyloxy)]-1,2,5-thiadiazole

A solution of Compound 48 (0.9 g, 0.0037 mol) in DMF (25 mL) was treatedportionwise with freshly ground flaked Na₂ S-9H₂ O (0.97 g, 0.004 mol).After 2 h, the reaction was treated with dropwise with1-bromo-3-phenylpropane (1.11 g, 0.0059 mol), the reaction stirred 3.25h, followed by. dropwise addition of additional 1-bromo-3-phenylpropane(1.11 g, 0.0059 mol) in DMF (5 mL). After stirring overnight, thesolvents were evaporated, the residue suspended in H₂ O, acidified, andthe mixture extracted with ether. The aqueous phase was made basic,extracted with CHCl₃, the extracts dried, and the solvent evaporated.The residue purified by radial chromatography (MeOH:EtOAc:NH₄OH/15:30:1) to give an oil. The HCl salt (0.41 g) crystallized fromCHCl₃ -EtOAc-ether, m.p. 178°-179° C. (Compound 72)

EXAMPLE 69(±)3-[3-(4-Fluorophenyl)propylthio]-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole

A solution of the crude Compound 12 (1.15 g, 0.0047 mol) in DMF (20 mL)was treated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68 g,0.007 mol). After 1 h, 1-chloro-3-(4-fluorophenyl)propane (1.63 g,0.0095 mol) in DMF (2 mL) was added dropwise and the reaction stirred2.5 days. The reaction was then treated with additional1-chloro-3-(4-fluorophenyl)propane (0.815 g, 0.0047 mol) and warmed at35° C. for 6 h. The solvent was evaporated, the residue was acidifiedwith 1N HCl, and the mixture extracted with ether. The aqueous was madebasic and extracted with ether. The extracts were dried, the solventevaporated, and the residue purified by radial chromatography(MeOH:EtOAc:NH₄ OH/15:30:1). The HCl salt (0.19 g) crystallized fromCHCl₃ -EtOAc-ether, m.p. 189°-191° C. (Compound 73)

EXAMPLE 70(±)3-{3-[4-(Trifluoromethyl)phenyl]propylthio}-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole

A solution of the Compound 12 (1.15 g, 0.0047 mol) in DMF (20 mL) wastreated portionwise with freshly ground flaked Na₂ S-9H₂ O (1.68 g,0.007 mol). After 2 h, the reaction was cooled to -35° C., treateddropwise with 1-bromo-3-[4-(trifluoromethyl)phenyl)propane (2.53 g,0.0095 mol) in DMF (30 mL), and the reaction stirred 2 h. Cooling wasremoved, reaction stirred 3.5 h, and again cooled to -35° C. Thereaction was then treated with additional1-bromo-3-[4-(trifluoromethyl)phenyl)propane (1.75 g, 0.0043 mol) in DMF(5 mL), cooling removed, and reaction stirred over night. Additional1-bromo-3-[4-(trifluoromethyl)phenyl)propane (0.75 g, 0.0028 mol) in DMF(5 mL) was added and stirring continued for 1.5 h. The solvent wasevaporated, the residue suspended in H₂ O, and the mixture extractedwith ether. The extracts were dried, the solvent evaporated, and theresidue purified by radial chromatography (MeOH:EtOAc:NH₄ OH/15:30:1).The HCl salt (0.32 g) crystallized from CHCl₃ -EtOAc-ether, m.p.182°-184° C. (Compound 74)

EXAMPLE 713-(1-Butylamino)-4-[(+,-)-3-(azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole

A mixture of Compound 12 (1.15 g, 0.0047 mol) and 1-butylamine (20 mL)was heated to reflux for 22 h. The solvent was evaporated, residuesuspended in H₂ O, the mixture acidified, and extracted with ether. Theaqueous phase was made basic, extracted with EtOAc, extracts dried, andsolvent evaporated. Purification by radial chromatography(MeOH:EtOAc:NH₄ OH/15:30:1) and conversion to a HCl salt gave a solidpartial hydrate (0.046 g), m.p. 193°-195° C. (Compound 75)

EXAMPLE 72 Cyanogen Butyloxyimide

A solution of 1-butanol (92 mL, 1 mol) and triethylamine (3 mL) wascooled to -8° C. and cyanogen (58 g, 1.12 mol) was slowly bubbledthrough the solution while maintaining the temperature below 2° C. Thereaction mixture was then distilled at 7 mm Hg to give a clear liquid(119.4 g) b.p. 43°-49° C. (Compound 76).

EXAMPLE 73 3-Chloro-4-butyloxy-1,2,5-thiadiazole

A solution of DMF (400 mL) and sulfur monochloride (230 mL) was cooledto 5° C. and Compound 76 (119.4 g, 0.95 mol) was added dropwise suchthat the temperature did not exceed 10° C. Cooling was removed and thereaction was stirred over night. The reaction was cooled in an ice-waterbath and the excess sulfur monochloride destroyed by dropwise additionof H₂ O such that the temperature did not exceed 30° C. The liquid wasdecanted from the semi-solid sulfur precipitant and the sulfur residuetriturated with hexane. The aqueous fraction was extracted with hexane(3×) and the combined extracts and triturants were washed with H₂ O,aqueous NaHCO₃, brine, dried, and the solvent evaporated. The yellowliquid residue was distilled at 14 mm Hg to give a clear liquid (153 g),b.p. 120°-125° C. (Compound 77)

EXAMPLE 74 3-Methylthio-4-butyloxy-1,2,5-thiadiazole

A solution of Compound 77 (6 g, 0.031 mol) in DMF (75 mL) was rapidlystirred as ground flaked Na₂ S-9 H₂ O (8 g, 0.034 mol) was added. After1 h, CH₃ I (3 mL, 0.048 mol) was added and the reaction stirred 30 min.Ice-water (150 mL) was added to the reaction and the mixture extractedwith hexane (3×). The extracts were washed with H₂ O (2×), dried and thesolvent evaporated to give a clear liquid (6.04 g). (Compound 78)

EXAMPLE 75 3-Methylsulfonyl-4-butyloxy-1,2,5-thiadiazole

To a solution of Oxone (18.4 g, 0.03 mol) in H₂ O (100 mL) was addeddropwise Compound 78 (3 g, 0.0147 mol) in THF (45 mL). After stirringovernight, the organics were evaporated and the residue extracted withether (3×). The extracts were washed with H₂ O (2×), dried, and thesolvent evaporated. The residue was purified by radial chromatographyeluting with 50% EtOAc-hexane to give a clear colorless liquid (2.93 g)that solidified on standing, m.p. 39°-40° C. (Compound 79)

EXAMPLE 76 3-Methylthio-4-hexyloxy-1,2,5-thiadiazole

A solution of 3-chloro-4-hexyloxy-1,2,5-thiadiazole (CA 60, 2796e, 1964)(1.1 g, 0.005 mol) in DMF (30 mL) was rapidly stirred as ground flakedNa₂ S-9 H₂ O (1.5 g, 0.00625 mol) was added. After stirring overnight,CH₃ I (2 mL ) was added and the reaction stirred 30 min. Ice-water (150mL) was added to the reaction and the mixture extracted with ether (2×).The extracts were washed with H₂ O (2×), dried and the solventevaporated to give a clear liquid (1.025 g). (Compound 80)

EXAMPLE 77 3-Methylsulfonyl-4-hexyloxy-1,2,5-thiadiazole

To a solution of Oxone (18.4 g, 0.03 mol) in H₂ O (100 mL) was addeddropwise Compound 80 (3.4 g, 0.0147 mol) in THF (50 mL). After stirringfor three days, the organics were evaporated and the residue extractedwith ether (3×). The extracts were washed with H₂ O (2×), dried, and thesolvent evaporated. The residue was purified by radial chromatographyeluting with 50% EtOAc-hexane to give a clear colorless liquid (3.58 g).(Compound 81)

EXAMPLE 78 Cyanogen Propyloxyimide

A solution of 1-propanol (40 mL, 0.536 mol) and triethylamine (1.5 mL)was cooled to -8° C. and cyanogen (36 g, 0.69 mol) was slowly bubbledthrough the solution while maintaining the temperature below 2° C. Thereaction mixture was then distilled at 20 mm Hg to give a clear liquid(59 g) b.p. 63°-64° C. (Compound 82)

EXAMPLE 79 3-Chloro-4-propyloxy-1,2,5-thiadiazole

A solution of DMF (180 mL) and sulfur monochloride (120 mL, 1.5 mol) wascooled to 5° C. and Compound 82 (59 g, 0.527 mol) was added dropwisesuch that the temperature did not exceed 10° C. Cooling was removed andthe reaction was stirred over night. The reaction was cooled in anice-water bath and the excess sulfur monochloride destroyed by dropwiseaddition of H₂ O such that the temperature did not exceed 30° C. Theliquid was decanted from the semi-solid sulfur precipitant and thesulfur residue triturated with hexane. The aqueous fraction wasextracted with hexane (3×) and the combined extracts and triturants werewashed with H₂ O, aqueous NaHCO₃, brine, dried, and the solventevaporated. The yellow liquid residue was distilled at 15 mm Hg to givea clear liquid (79.9 g), b.p. 103°-106° C. (Compound 83)

EXAMPLE 80 3-Methylthio-4-propyloxy-1,2,5-thiadiazole

A solution of Compound 83 (11.1 g, 0.062 mol) in DMF (150 mL) wasrapidly stirred as ground flaked Na₂ S-9 H₂ O (16.4 g, 0.068 mol) wasadded. After 1 h, CH₃ I (6 mL, 0.096 mol) was added and the reactionstirred 30 min. Ice-water (300 mL) was added to the reaction and themixture extracted with hexane (3×). The extracts were washed with H₂ O(2×), dried and the solvent evaporated to give a clear liquid (11.02 g).(Compound 84)

EXAMPLE 81 3-Methylsulfonyl-4-proploxy-1,2,5-thiadiazole

To a solution of Oxone (20 g, 0.0325 mol) in H₂ O (100 mL) was addeddropwise Compound 84 (3 g, 0.0158 mol) in THF (50 mL). After stirringovernight, the organics were evaporated and the residue extracted withether (3×). The extracts were washed with H₂ O (2×), dried, and thesolvent evaporated to give a colorless oil. The residue was purified byradial chromatography eluting with 40% EtOAc-hexane to give a clearcolorless liquid (3.09 g) that solidified on standing. Recrystallizationfrom hexane gave a white solid, m.p. 30°-31° C. (Compound 85)

EXAMPLE 82 Cyanogen Methoxyimide

A solution of methanol (25 mL, 0.618 mol) and triethylamine (1.5 mL) wascooled to -8° C. and cyanogen (38 g, 0.73 mol) was slowly bubbledthrough the solution while maintaining the temperature below 2° C. Thereaction mixture was then distilled at 45 mm Hg to give a clear liquid(51 g) b.p. 48°-53° C. (Compound 86)

EXAMPLE 83 3-Chloro-4-methoxy-1,2,5-thiadiazole

A solution of DMF (180 mL) and sulfur monochloride (120 mL, 1.5 mol) wascooled to 5° C. and Compound 86 (51 g, 0.607 mol) was added dropwisesuch that the temperature did not exceed 15° C. Cooling was removed andthe reaction was stirred over night. The reaction was cooled in anice-water bath and the excess sulfur monochloride destroyed by dropwiseaddition of H₂ O such that the temperature did not exceed 30° C. Thesolution was further diluted with H₂ O (350 mL) and steam distilleduntil almost all of the distillate was homogeneous. The distillate wasextracted with hexane (3×) and the combined extracts washed with H₂ O,aqueous NaHCO₃, brine, dried, and the solvent distilled off until thevolume was 200 mL. The hot mixture was filtered and cooled to give whitecrystals (53 g). (Compound 87)

EXAMPLE 84 3-Methylthio-4-methoxy-1,2,5-thiadiazole

A solution of Compound 87 (9.4 g, 0.0623 mol) in DMF (150 mL) wasrapidly stirred as ground flaked Na₂ S-9 H₂ O (16.4 g, 0.068 mol) wasadded. After 1 h, CH₃ I (6 mL, 0.096 mol) was added and the reactionstirred 30 min. Ice-water (300 mL) was added to the reaction and themixture extracted with hexane (3×). The extracts were washed with H₂ O(2×), dried and the solvent carefully evaporated to give a clear liquid(4.4 g). (Compound 88)

EXAMPLE 85 3-Methylsulfonyl-4-methoxy-1,2,5-thiadiazole

To a solution of Oxone (34 g, 0.0552 mol) in H₂ O (170 mL) was addeddropwise Compound 88 (4.4 g, 0.027 mol) in THF (80 mL). After stirring 5h, the organics were evaporated and the residue extracted with ether(3×). The extracts were washed with H₂ O (2×), dried, and the solventevaporated to give a floculant white solid. Recrystallization from ethergave a white solid (2.76 g), m.p. 110.5°-111.5° C. (Compound 89)

EXAMPLE 86 3-Chloro-4-pentyloxy-1,2,5-thiadiazole

A solution of 1-pentanol (60 mL, 0.55 mol) and triethylamine (1.5 mL)was cooled to -8° C. and cyanogen (36 g, 0.69 mol) was slowly bubbledthrough the solution while maintaining the temperature below 2° C. Thereaction was then stirred another hour at -5° C. then added dropwise toa solution of DMF (180 mL) and sulfur monochloride (120 mL, 1.5 mol)that was cooled to 5° C. while maintaining the temperature of the DMFsolution below 10° C. Cooling was removed and the reaction was stirredover night. The reaction was cooled in an ice-water bath and the excesssulfur monochloride destroyed by dropwise addition of H₂ O such that thetemperature did not exceed 30° C. The liquid was decanted from thesemi-solid sulfur precipitant and the sulfur residue triturated withhexane. The aqueous fraction was extracted with hexane (3×) and thecombined extracts and triturants were washed with H₂ O, aqueous NaHCO₃,brine, dried, and the solvent evaporated. The yellow liquid residue wasdistilled at 9 mm Hg to give a clear liquid (92.7 g), b.p. 129°-135° C.(Compound 90)

EXAMPLE 87 3-Methylthio-4-pentyloxy-1,2,5-thiadiazole

A solution of Compound 90 (12.8 g, 0.06 mol) in DMF (150 mL) was rapidlystirred as ground flaked Na₂ S-9 H₂ O (16.4 g, 0.068 mol) was added.After 1 h, CH₃ I (6 mL, 0.096 mol) was added and the reaction stirred 30min. Ice-water (300 mL) was added to the reaction and the mixtureextracted with hexane (3×). The extracts were washed with H₂ O (2×),dried and the solvent evaporated to give a clear liquid (12.6 g).(Compound 91)

EXAMPLE 88 3-Methylsulfonyl-4-pentlyoxy-1,2,5-thiadiazole

To a solution of Oxone (72 g, 0.117 mol) in H₂ O (350 mL) was addeddropwise Compound 91 (12.4 g, 0.0569 mol) in THF (180 mL). Afterstirring overnight, the organics were evaporated and the residueextracted with ether (3×). The extracts were washed with H₂ O (2×),dried, and the solvent evaporated to give a colorless oil. The residuewas purified by flash chromatography eluting with 40% EtOAc-hexane togive a clear colorless liquid (13 g). (Compound 92)

EXAMPLE 89 3-Chloro-4-ethoxy-1,2,5-thiadiazole

A solution of ethanol (60 mL, 1.02 mol) and triethylamine (1.5 mL) wascooled to -8° C. and cyanogen (59 g, 1.13 mol) was slowly bubbledthrough the solution while maintaining the temperature below 2° C. Thereaction was then added dropwise to a solution of DMF (275 mL) andsulfur monochloride (225 mL, 2.81 mol) that was cooled to 5° C. whilemaintaining the temperature of the DMF solution below 10° C. Cooling wasremoved and the reaction was stirred over night. The reaction was cooledin an ice-water bath and the excess sulfur monochloride destroyed bydropwise addition of H₂ O such that the temperature did not exceed 30°C. Additional H₂ O (400 mL) was added and the reaction internally steamdistilled until the distillate was almost homogeneous. The distillatewas extracted with hexane (3×) and the combined extracts washed with H₂O, aqueous NaHCO₃, brine, dried, and the solvent carefully evaporated.The liquid residue was distilled at 21 mm Hg to give a clear liquid(154.3 g), b.p. 88°-93° C. (Compound 93)

EXAMPLE 90 3-Methylthio-4-ethoxy-1,2,5-thiadiazole

A solution of Compound 93 (16.5 g, 0.1 mol) in DMF (250 mL) was rapidlystirred as ground flaked Na₂ S-9 H₂ O (27 g, 0.113 mol) was added. After1 h, CH₃ I (9.5 mL, 0.153 mol) was added and the reaction stirred 1 h.Ice-water (400 mL) was added to the reaction and the mixture extractedwith hexane (3×). The extracts were washed with H₂ O (2×), dried and thesolvent evaporated to give a clear liquid (12.5 g). (Compound 94)

EXAMPLE 91 3-Methylsulfonyl-4-ethoxy-1,2,5-thiadiazole

To a solution of Oxone (90 g, 0.146 mol) in H₂ O (435 mL) was addeddropwise 19 (12.5 g, 0.071 mol) in THF (220 mL). After stirringovernight, the organics were evaporated and the residue extracted withether (3×). The extracts were washed with H₂ O (2×), dried, and thesolvent evaporated to give a white solid. Recrystallization from ethergave a white solid (9.9 g), m.p. 94°-95° C. (Compound 95)

EXAMPLE 92 3-Chloro-4-(4-methylpentyloxy)-1,2,5-thiadiazole

A solution of 4-methylpentan-1-ol (25 mL, 0.245 mol) and triethylamine(1 mL) was cooled to -8° C. and cyanogen (14 g, 0.27 mol) was slowlybubbled through the solution while maintaining the temperature below 2°C. The reaction was then stirred another hour at -5° C. then addeddropwise to a solution of DMF (75 mL) and sulfur monochloride (49 mL)that was cooled to 5° C. while maintaining the temperature of the DMFsolution below 10° C. Cooling was removed and the reaction was stirredover night. The reaction was cooled in an ice-water bath and the excesssulfur monochloride destroyed by dropwise addition of H₂ O such that thetemperature did not exceed 35° C. The liquid was decanted from thesemi-solid sulfur precipitant and the sulfur residue triturated withhexane. The aqueous fraction was extracted with hexane (3×) and thecombined extracts and triturants were washed with H₂ O, aqueous NaHCO₃,brine, dried, and the solvent evaporated. The yellow liquid residue wasdistilled at 4.5 mm Hg to give a clear liquid (40.45 g), b.p. 120°-124°C. (Compound 96)

EXAMPLE 93 3-Methylthio-4-(4-methylpentyloxy)-1,2,5-thiadiazole

A solution of Compound 96 (22 g, 0.1 mol) in DMF (250 mL) was rapidlystirred as ground flaked Na₂ S-9 H₂ O (27 g, 0..113 mol) was added.After 1 h, CH₃ I (9.5 mL, 0.153 mol) was added and the reaction stirred30 min. Ice-water (300 mL) was added to the reaction and the mixtureextracted with hexane (3×). The extracts were washed with H₂ O (2×),dried and the solvent evaporated to give a clear liquid (21.6 g).(Compound 97)

EXAMPLE 94 3-Methylsulfonyl-4-(4-methylpentyloxy)-1,2,5-thiadiazole

To a solution of Oxone (119 g, 0.193 mol) in H₂ O (600 mL) was addeddropwise Compound 97 (21.6 g, 0.093 mol) in THF (300 mL). After stirringovernight, the organics were evaporated and the residue extracted withether (3×). The extracts were washed with H₂ O (2×), dried, and thesolvent evaporated to give a colorless oil. The residue was purified byHPLC (8 L gradient, hexane to 40% EtOAc-hexane) to give a clearcolorless liquid (19.7 g). (Compound 98)

EXAMPLE 953-(1-Butyloxy)-4-[endo-(+,-)-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole

A solution of potassium t-butoxide (0.62 g, 0.0055 mol) in THF (12 mL)was treated with endo-(+,-)-1-azabicyclo[3.2.1]octan-6-ol (0.64 g, 0.005mol). After 5 min, 3-chloro-4-(1-butyloxy)-1,2,5-thiadiazole (1.5 g,0.0072 mol) was added. After stirring overnight, the solvent wasevaporated, the residue diluted with H₂ O, acidified, and extracted withether. The aqueous phase was made basic and extracted with EtOAc, theextracts dried, washed with brine, dried, and the solvent evaporated.The residue was purified by radial chromatography (20% EtOH-2% NH₄OH-CHCl₃). The HCl salt crystallized from EtOAc to give a white solid(0.21 g), m.p. 172°-173° C. dec. (Compound 71)

EXAMPLE 96(±)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 3-(2-methylthioethyl)-4-hydroxy-1,2,5-thiadiazole (0.45 g)and triphenylphosphine (0.7 g) was cooled in ice-water asdiethyldiazodicarboxylate (0.4 mL) was added dropwise. After addition,(±)-1-azabicyclo[2.2.2]octan-3-ol (0.33 g) was added, cooling removed,and reaction stirred for 1 hour. The solvent was evaporated, residuesuspended in water, the mixture acidified and washed with ether. Theaqueous solution was made basic and extracted with EtOAc. The extractswere dried, the solvent evaporated, the residue purified by radialchromotography eluting with 10%-EtOH-1%-NH₄ OH-CHCl₃, and the productconverted to a HCl salt. Recrystallization from acetone gave 0.6 g whitecrystals, m.p. 177°-178° C. (Compound 99).

The following compounds were synthesized in substantially the samemanner as Compound 99.

EXAMPLE 97 (±)-3-(1-Azabicyclo[2.2.2]otyl-3-oxy)-1,2,5-thiadiazole

A sample of 3-Hydroxy-1,2,5-thiadiazole (0.28 g), triphenylphospine (0.7g), diethyldiazodicarboxylate (0.4 mL), and(±)-1-azabicyclo[2.2.2]octan-3-ol (0.33 g) gave the hydrochloride saltof (±)-3-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole, m.p. 240°C. dec. (0.36 g). (Compound 100).

EXAMPLE 98(±)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A sample of 3-Hexyl-4-Hydroxy-1,2,5-thiadiazole (0.93 g),triphenylphospine (1.31 g), diethyldiazodi-carboxylate (0.8 mL), and(±)-1-azabicyclo[2.2.2]octan-3-ol (0.64 g) gave the hydrochloride saltof (±)-3-hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,m.p. 163°-164° C. dec. (1.11 g). (Compound 101).

EXAMPLE 99(±)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of potassium t-butoxide (1.2 g) in THF (50 mL) was treatedwith (±)-1-azabicyclo[2.2.2]octan-3-ol (1.3 g). After 10 min, thereaction was cooled in ice-water and Compound 1 (2.3 g) was added in oneportion. Cooling was removed and after two hours the solution was heatedto reflux for 4 hours. The solvent was evaporated, residue suspended inwater, the mixture acidified and extracted with ether. The aqueousfraction was made basic and extracted with EtOAc. The extracts werewashed with water brine, dried, and the solvent evaporated to giveCompound 14 (1.95 g). The oil was dissolved in dilute 0.5N HCl (17 mL),cooled in ice-water, and a solution of Oxone (6 g) in water (25 mL) wasadded over 5 min. Cooling was removed and after 4 hours excess oxidizingagent was destroyed with NaHSO₃. The reaction was cooled in ice-water,made basic with 5N NaOH, and extracted with EtOAc. The extracts werewashed with brine, dried, and the solvent evaporated to give(±)-3-butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas a yellow oil (1.6 g). The HCl salt crystallized from 2-propanol as awhite solid, m.p. 180°-181° C. (Compound 102)

EXAMPLE 100 (±)-3 -Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure as for Compound 102,(±)-1-azabicyclo[2.2.2]octan-3-ol (4 g) and Compound 37 (4.9 g) gave(±)-3-propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(4.2 g) as a tan liquid that solidified on standing, m.p. 77°-78° C.(Compound 103).

EXAMPLE 101(±)-3-(4,4,4-Trifluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 4,4,4-trifluorobutanol (0.75 g) in THF (20 mL) was cooledto 0° C. and potassium t-butoxide (0.65 g) was added. After 5 min, asolution of Compound 102 (0.6 g) in THF (5 mL) was added and thereaction stirred one hour. The reaction was quenched with 5N HCl (1.5mL) and the solvent evaporated. The residue was suspended in water andextracted with ether. The aqueous phase was made basic and extractedwith EtOAc. The extracts were dried, the solvent evaporated, and theresidue purified by radial chromotography eluting with 20%-EtOH-1%-NH₄OH-CHCl₃ to give a clear oil. The HCl salt was recrystallized fromEtOAc-ether to give a white solid, m.p. 122°-124° C. (0.43 g). (Compound104).

The following compounds were prepared in substantially the same manner:

EXAMPLE 102(±)-3-(2-butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 2-butynol (0.45 g) and Compound 102 (0.6 g) gave afterchromatography,(±)-3-(2-butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.45 g) as an HCl salt that crystallized from 2-propanol, m.p.200°-201° C. (Compound 105)

EXAMPLE 103(±)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, cyclopropylmethanol (0.5 mL) and Compound 102 (0.6 g) gave afterchromatography,(±)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.49 g) as an HCl salt that crystallized from acetone, m.p. 217°-218°C. (Compound 106)

EXAMPLE 104 (±)-3 -(3-Phenylpropynloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 3-phenylpropynol (0.85 g) and Compound 102 (0.66 g) gaveafter chromatography(±)-3-(3-phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.66 g) that crystallized from ether-CHCl₃, m.p.184°-186° C. (Compound 107)

EXAMPLE 105(±)-3-(3-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 3-butenol (0.5 mL) and Compound 102 (0.6 g) gave afterchromatography,(±)-3-(3-butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.47 g) as an HCl salt that crystallized from acetone, m.p. 198°-199°C. (Compound 108).

EXAMPLE 106(±)-3-(trans-2-Butenyloxy)-4-(1-azabicylo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, trans-2-butenol (0.45 g) and Compound 102 (0.6 g) gave afterchromatography,(±)-3-(trans-2-butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.51 g) as an HCl salt that crystallized from 2-propanol, m.p.182.5°-184° C. (Compound 109).

EXAMPLE 107 (±)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, cis-2-butenol (0.45 g) and Compound 102 (0.5 g) gave afterchromatography,(±)-3-(cis-2-butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.34 g) as an HCl salt that crystallized from acetone, m.p. 178°-179°C. (Compound 110).

EXAMPLE 108(±)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 2-methoxyethanol (0.45 g) and Compound 102 (0.5 g) gave afterchromatography,(±)-3-(2-methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.32 g) as an HCl salt that crystallized from acetone, m.p. 131°-134°C. (Compound 111).

EXAMPLE 109(±)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-phenoxyethanol (0.55 g) and Compound 102 (0.4 g) gave(±)-3-(2-phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.43 g) that crystallized from ether-CHCl₃, m.p.213°-215° C. (Compound 112).

EXAMPLE 110(±)-3-(9-Butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 3-butynol (0.27 g) and Compound 102 (0.4 g) gave afterchromatography(±)-3-(3-butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.19 g) that crystallized from ether-CHCl₃, m.p.207°-208° C. (Compound 113).

EXAMPLE 111(±)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 2-cyclopropylethanol (0.52 g) and Compound 102 (0.5 g) gave afterchromatography,(±)-3-(2-cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.48 g) as an HCl salt that crystallized from acetone, m.p. 192°-193°C. (Compound 114).

EXAMPLE 112(±)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 2-(methylthio)ethanol (0.52 mL) and Compound 102 (0.5 g) gave afterchromatography,(±)-3-(2-(methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.4 g) as an HCl salt that crystallized from acetone, m.p. 187°-188° C.(Compound 115)

EXAMPLE 113(±)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 3-chloropropanol (0.5 mL) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(3-chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.25 g) as an HCl salt that crystallized from acetone-EtOAc, m.p.167°-168° C. (Compound 116).

EXAMPLE 114(±)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 4-fluorobutanol (0.6 g) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(4-fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-1,2,5-thiadiazole(0.34 g) as an HCl salt that crystallized from acetone-EtOAc, m.p.180.5°-181.5° C. (Compound 117).

EXAMPLE 115(±)-3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-(4-chlorophenoxy)ethanol (0.77 g) and Compound 102 (0.4g) gave after chromatography(±)-3-(2-[4-chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.44 g) that crystallized from ether-CHCl₃, m.p.224°-226° C. (Compound 118).

EXAMPLE 116(±)-3-(3-[2-Methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 3(2-methoxy-5-pyridyl)propanol (0.75 g) and Compound 102(0.4 g) gave after chromatography(±)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.48 g) that crystallized from ether-CHCl₃, m.p.148°-150° C. (Compound 119).

EXAMPLE 117(±)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxyl-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104 except that the reaction was conducted at -15° C.,trans-3-chloro-2-propenol (0.5 g) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(trans-3-chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.33 g) as an HCl salt that crystallized from acetone, m.p.176.5°-177.5° C. (Compound 120).

EXAMPLE 118(±)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-(4-fluorophenoxy)ethanol (0.53 g) and Compound 102 (0.4g) gave after chromatography(±)-3-(2-[4-fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.43 g) that crystallized from ether-CHCl₃, m.p.187°-189° C. (Compound 121).

EXAMPLE 119(±)-3-(4-Pentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 4-pentenol (0.6 mL) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(4-pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.37 g) as an HCl salt that crystallized from EtOAc, m.p. 165°-166° C.(Compound 122).

EXAMPLE 120(±)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, 3-fluoropropanol (0.4 g) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(3-fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.3 g) as an HCl salt that crystallized from acetone, m.p. 206°-207° C.(Compound 123).

EXAMPLE 121 (±)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation Compound104, cyclobutylmethanol (0.6 mL) and Compound 102 (0.4 g) gave afterchromatography,(±)-3-(cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.33 g) as an HCl salt that crystallized from acetone, m.p. 212°-213°C. (Compound 124).

EXAMPLE 122(±)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 3,3,3,2,2-heptafluoropropanol (0.69 g) and Compound 102(0.4 g) gave after chromatography(±)-3-(3,3,3,2,2-heptafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.44 g) that crystallized from ether-CHCl₃, m.p.185°-186° C. (Compound 125).

EXAMPLE 123(±)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-(phenylthio)ethanol (0.71 g) and Compound 102 (0.4 g)gave after chromatography(±)-3-(2-[phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.37 g) that crystallized from ether-CHCl₃, m.p.187°-189° C. (Compound 126).

EXAMPLE 124 (±)-3-(2-[1-Napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-(1-napthyloxy)ethanol (0.839 g) and Compound 102 (0.4 g)gave after chromatography(±)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.51 g) that crystallized from ether-CHCl₃, m.p.223°-225° C. (Compound 127).

EXAMPLE 125(±)-3-(2-[4-Bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofCompound 104, 2-(4-bromophenoxy)ethanol (0.97 g) and Compound 102 (0.4g) gave after chromatography(±)-3-(2-[4-bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole as an HCl salt (0.53 g) that crystallized from ether-CHCl₃,m.p. 223°-224° C. (Compound 128).

EXAMPLE 126(±)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of ethylene glycol (9 mL) and potassium t-butoxide (1.5 g)was treated with Compound 102 (0.8 g). After stirring over night, thereaction was heated to 55° C. for 1 h. The reaction was then cooled,diluted with water, and extracted with EtOAc. The extracts were washedwith brine, dried, and the solvent evaporated to give a clear liquid.The liquid was purified by radial chromatography eluting with20%-EtOH-2%-NH₄ OH-CHCl₃ and then crystallized from ether to give awhite solid (0.45 g), m.p. 119.5°-120.5° C. (Compound 129)

EXAMPLE 127 3-Butylthio-4-hydroxy-1,2,5-thiadiazole

A solution of Compound 1 (20.9 g), DMSO (20 mL) and 2N NaOH (205 mL) washeaded to reflux overnight. The solution was cooled to 15° C. andconcentrated HCl was added until the pH was 1. The solid was collected,washed with water, and dried to give a solid (17.68 g).Recrystallization from heptane gave white crystals, m.p. 72°-72.5° C.(Compound 130).

EXAMPLE 128(±)exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole

A solution of triphenylphosphine (0.7 g) and Compound 130 (0.5 g) in THF(20 mL) was cooled in ice-water. Diethyl diazodicarboxylate (0.4 mL) wasadded dropwise followed by addition of(±)endo-3-hydroxy-1-azabicyclo[2.2.1]heptane (0.29 g). Cooling wasremoved and after 1 h the solvent was evaporated. The residue wassuspended in cold water, acidified, and extracted with ether. Theaqueous fraction was made basic and extracted with EtOAc. The extractswere dried, the solvent evaporated, and the residue purified by radialchromatography eluting with 5%-EtOH-0.5% NH₄ OH-CHCl₃ to give a clearoil. The HCl salt crystallized from EtOAc as white crystals (0.44 g),m.p. 147°-148° C. (Compound 131).

EXAMPLE 129(±)-3-(2-[9-{1,2,5-Thiadiazoylxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of triphenylphosphine (0.35 g) and3-hydroxy-1,2,5-thiadiazole (0.14 g) in THF (15 mL) was cooled inice-water. Diethyl diazodicarboxylate (0.21 g) was added dropwisefollowed by(±)-3-(2-hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.35 g). Cooling was removed, reaction was stirred 1 h, and the solventwas evaporated. The residue was suspended in cold water, acidified, andextracted with ether. The aqueous fraction was made basic and extractedwith EtOAc. The extracts were washed with brine, dried, the solventevaporated, and the residue purified by radial chromatography elutingwith 10%-EtOH-1% NH₄ OH-CHCl₃ to give a clear oil. The HCl saltcrystallized from acetone as a white powder (0.34 g), m.p. 178°-179° C.(Compound 132).

EXAMPLE 130(±)-exo-3-Butyloxy-4-(7-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole

A solution of exo-7-azabicyclo[2.2.1]heptan-3-ol (0.4 g)(Ref. J. Org.Chem. 1994, 59, 1771) in THF (25 mL) was cooled in ice-water and treateddropwise with 1.6M n-butyllithium in hexane (3.5 mL). Cooling wasremoved and, after 15 min, compound 79 (0.65 g) was added. After another45 min, the reaction was heated to reflux over night. The solvent wasevaporated, the residue suspended in water, the mixture acidified, andextracted with ether. The aqueous fraction was made basic and extractedwith EtOAc. The extracts were dried, the solvent evaporated, and theresidue purified by radial chromatography eluting with 5%-EtOH-0.5% NH₄OH-CHCl₃ then 10%-EtOH-1% NH₄ OH-CHCl₃ to give a clear oil. The HCl saltcrystallized from EtOAc-ether as floculant white crystals (0.4 g), m.p.116°-117° C. (Compound 133).

EXAMPLE 131 (±)-3-Butyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole

A suspension of (±)-3-hydroxypiperidine hydrochloride (0.5 g) in THF (20mL) was treated dropwise with 1.6M n-butyllithium in hexane (4.6 mL).After 1 h, compound 79 (0.6 g) was added and the reaction was heated toreflux for 6.5 h. The solvent was evaporated, the residue suspended incold water, acidified, and extracted with ether. The aqueous fractionwas made basic and extracted with CHCl₃. The extracts were dried, thesolvent evaporated, and the residue purified by radial chromatographyeluting with 10%-EtOH-1% NH₄ OH-CHCl₃ to give a clear oil. The HCl saltcrystallized from EtOAc as a white solid (0.38 g), m.p. 124°-125° C.(Compound 134).

EXAMPLE 1323-Butyloxy-4-(cis-1R-2-aminocyclopentanoxy)-1,2,5-thiadiazole

A suspension of cis-1R-2-aminocyclopentanol hydrochloride (0.35 g) inTHF (25 mL) was cooled in ice-water as 1.6M n-butyllithium in hexane(3.2 mL) was added. Cooling was removed and after 30 min, compound 79(0.3 g) was added and the reaction was heated to reflux for 1 h.Additional compound 79 (0.3 g) was added and the reaction heated toreflux over night. The solvent was evaporated, the residue suspended inice-water, acidified, and extracted with ether. The aqueous fraction wasmade basic, extracted with CHCl₃, the extracts dried, the solventevaporated, and the residue purified by raidal chromatography elutingwith 10%-EtOH-1% NH₄ OH-CHCl₃ to give a straw colored oil. The HCl saltcrystallized ether as a tan solid (0.19 g), m.p. 105°-106.5° C.(Compound 135).

EXAMPLE 133(±)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of potassium tert-butoxide 0.65 g) in THF (15 mL) was treatedwith (±)-endo-1-azabicyclo[3.2.1]octan-6-ol (0.64 g). After 10 min,3-chloro-4-hexyloxy-1,2,5-thiadiazole (1.4 g) was added and the reactionstirred for 3 days. The solvent was evaporated, the residue suspended inice-water, the mixture acidified, and extracted with ether. The aqueousfraction was made basic, extracted with EtOAc, the extracts dried andthe solvent evaporated. The residue was purifed by radial chromatographyeluting with 20%-EtOH-2%-NH₄ OH-CHCl₃ to give a clear oil (0.5 g). TheHCl salt crystallized from EtOAc to give a white solid, m.p. 160°-161°C. (Compound 136).

The resolved enantiomers of endo-1-azabicyclo[3.2.1]octan-6-ol wereobtained by the reduction of the resolved ketones (reference the Novopatent) as described in reference.

EXAMPLE 134 (5S,6S)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of potassium tert-butoxide (0.65 g) in THF (25 mL) wastreated with (5S, 6S)-endo-1-azabicyclo[3.2.1]octan-6-ol (0.65 g). After5 min, the reaction was cooled in ice-water and compound 1 (1.2 g) wasadded. Cooling was removed and the reaction was stirred over night. Thesolvent was evaporated, the residue suspended in ice-water, and themixture acidified and extracted with ether. The aqueous fraction wasmade basic, extracted with EtOAc, the extracts dried, the solventevaporated, and the residue purified by radial chromatography elutingwith 20%-EtOH-2% NH₄ OH-CHCl₃ to give an oil. The HCl salt crystallizedfrom EtOAc as floculant white crystals (0.59 g), m.p. 201° C., [α]_(D)=11.44° (EtOH). (Compound 137).

EXAMPLE 135(5R,6R)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Using the procedure described for the preparation of Compound 137, (5R,6R)-endo-1-azabicyclo[3.2.1]octan-6-ol (0.65 g), potassium tert-butoxide(0.65 g) and compound 1 (1.2 g) gave floculant white crystals of the HClsalt of 334559 (0.62 g), m.p. 201°-202° C., [α]_(D) =-12.33° (EtOH).(Compound 138)

EXAMPLE 136 1-azabicyclo[4.3.0]nona-6,8-diene-5-one

A solution of Ethyl-4-(N-pyrrolo)butanoate (ref. Tetrahedron Letters1994, 35, 3905) (3.64 g) in CH₂ Cl₂ (400 mL) was treated dropwise with1M BBr₃ in CH₂ Cl₂ (60 mL). After 30 min, the reaction was quenched withwater (50 mL) and neutralized with aqueous NaHCO₃.The organics wereseparated, washed with aqueous NaHCO₃, brine, dried, and the solventevaporated. The residue was purified by hplc using a 10%-EtOAc-hexane to30% EtOAc-hexane gradient to give an oil (5.2 g). (Compound 139).

EXAMPLE 137 (±)-cis+trans-1-Azabicyclo[4.3.0]nonan-5-ols

A mixture of Compound 139 (5.2 g), 5% Rh/Al₂ O₃ (1.3 g), in EtOH (95 mL)was treated with H₂ at 60 psi for 2 h. Another aliquote of 5% Rh/Al₂ O₃(1.3 g) was added and hydrogenation was continued over night. Thecatalyst was removed and solvent evaporated to give an oil (4.2 g) thathad appropriate mass spectrum for the alcohols, m/e=141. (Compound 140).

EXAMPLE 138(±)-trans-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole

A solution of Compound 140 (0.7 g) in THF (20 mL) was treated withpotassium tert-butoxide (0.6 g). After 5 min, compound 1 (1.1 g) wasadded, the reaction stirred 1 h, then heated to reflux 1 h. The solventwas evaporated, the residue suspended in ice-water, and the mixtureacidified. After extracting with ether, the aqueous fraction was madebasic and extracted with EtOAc. The EtOAc extracts were dried, thesolvent evaporated, and the residue purified by radial chromatographyeluting with 5%-EtOH-0.5% NH₄ OH-CHCl₃ to give an oil. The HCl saltcrystallized from EtOAc as a white solid (0.21 g), m.p. 162°-163° C.(Compound 141).

EXAMPLE 139(±)-cis-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole

Further elution during the chromatographic purification of Compound 141gave another clear oil. The HCl crystallized from EtOAc as a white solid(0.18 g), m.p. 125°-126° C. (Compound 142).

EXAMPLE 140(±)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole

A solution of potassium tert-butoxide (0.7 g) in THF (20 mL) was treatedwith (±)-trans-2-dimethylaminocyclopentanol (0.8 g). After 10 min, thereaction was cooled in ice-water and compound 1 (1.25 g) was added.Cooling was removed and the reaction was stirred over night. Afterheating to reflux for 2 h, the solvent was evaporated, the residuesuspended in ice-water, and the mixture acidified. The mixture wasextracted with ether and the aqueous phase made basic. Extraction withEtOAc, drying of the extracts, evaporation of the solvent, andpurification by radial chromatography eluting with 10%-EtOH-1% NH₄OH-CHCl₃ gave a tan liquid. The HCl salt crystallized from EtOAc-etherto give a white solid (0.55 g), m.p. 124°-125° C. (Compound 143).

EXAMPLE 141 3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole

A solution of potassium tert-butoxide (0.6 g) in THF (20 mL) was treatedwith 2-dimethylaminoethanol (0.5 mL). After 5 min, compound 1 (1.05 g)was added and the reaction stirred 2 h. The solvent was evaporated,residue suspended in ice-water, and the mixture acidified. The mixturewas extracted with ether then the aqueous fraction made basic.Extraction with EtOAc, drying of the extracts, evaporation of thesolvent, and purification of the residue by radial chromatographyeluting with 5%-EtOH-0.5% NH₄ OH-CHCl₃ gave an oil. The HCl saltcrystallized from EtOAc as a white solid (0.47 g), m.p. 104°-105° C.(Compound 144).

EXAMPLE 142(±)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrollidin-3-oxy)-1,2,5-thiadiazole

A mixture of NaOH (0.12 g) and DMF (15 mL) was treated with Compound 130(0.95 g) and the reaction stirred 1 h. The solution was treated with3,4-epoxy-N-tert-butylcarboxypyrollidine (0.8 g) and the solution heatedat 60° C. over night. The temperature of the reaction was then increasedto 110° C. for 7.5 h. The solvent was evaporated, the residue suspendedin ice-water, and the mixture extracted with EtOAc. The extracts werewashed with water, brine, the extracts dried, and the solventevaporated. The residue was purified by radial chromatography elutingwith 50% EtOAc-hexane to give an oil (0.44 g). (Compound 145).

EXAMPLE 143(±)-trans-3-Butylthio-4-(4-hydroxy-pyrollidin-3-oxy)-1,2,5-thiadiazole

A solution of Compound 145 (0.44 g) in EtOAc (15 mL) was cooled inice-water as a stream of dry HCl was introduced for 2 min. Cooling wasremoved and after 5 min the solvent was evaporated. The residue wasdissolved in cold water, extracted with ether, and the aqueous phasemade basic. The aqueous was extracted with EtOAc, the extracts dried,the solvent evaporated, and the residue purified by radialchromatography eluting with 20%-EtOH-2% NH₄ OH-CHCl₃ to give a whitesolid. The HCl salt crystallized from acetone-ether as a white solid(0.23 g), m.p. 106°-108° C. (Compound 146).

EXAMPLE 144(±)-endo-3-Butyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of potassium tert-butoxide 0.62 g) in THF (10 mL) was treatedwith (±)-endo-1-azabicyclo[3.2.1]octan-6-ol (0.64 g). After 5 min, thereaction was cooled in ice-water, compound 77 (1.5 g) was added, coolingwas removed, and the reaction stirred over night. The solvent wasevaporated, the residue suspended in ice-water, the mixture acidified,and the mixture extracted with ether. The aqueous fraction was madebasic, extracted with EtOAc, the extracts dried, the solvent evaporated,and the residue purified by radial chromatography eluting with20%-EtOH-2% NH₄ OH-CHCl₃. The HCl salt crystallized from EtOAc to give awhite solid (0.21 g), m.p. 172°-173° C. (Compound 147).

EXAMPLE 145(±)-3-(4-Phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 40, compound 12 (1.15 g) and 1-iodo-4-phenylbutane (4.92 g)gave(±)-3-(4-phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas a HCl salt (0.59 g) crystallizing from ether-EtOAc-CHCl₃, m.p.136°-139° C. (Compound 148).

EXAMPLE 146(±)-3-(3-Phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used for the preparation ofcompound 44, compound 12 (1.15 g) and cinnamyl bromide (3.73 g) gave(±)-3-(3-phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (0.095 g) crystallizing from ether-EtOAc-CHCl₃, m.p.211°-213° C. (Compound 149).

EXAMPLE 147(±)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2,2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 40, compound 12 (1.15 g) and1-chloro-3-(4-fluorophenyl)propan-3-one (3.52 g) gave(±)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole as a HCl salt (0.375 g) crystallizing fromether-EtOAc-CHCl₃, m.p. 203°-204° C. (Compound 150).

EXAMPLE 148(±)-3-(3-[N-phenothiazinyl]propylthio)-4(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 13, compound 12 (1.15 g) and1-bromo-3-(N-phenothiazinyl)propane (1.25 g) gave(±)-3-(3-[N-phenothiazinyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas a HCl salt (0.35 g) crystallizing from EtOAc, m.p. 194°-196° C.(Compound 151).

EXAMPLE 149(±)-3-(3-[4-Flourophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 13, compound 12 (1.15 g) and1-chloro-3-(4-fluorophenyl)-3-(4-fluorophenoxy)propane (2.6 g) gave(±)-3-(3-[4-fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an oxalate salt (0.42 g) crystallizing from EtOAc-ether, m.p. 87°-96°C. (Compound 152).

EXAMPLE 150(±)-3-(3-Phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 13, compound 12 (1.15 g) and 1-chloro-3-phenyl-3-(4-trifluoromethylphenoxy) propane (2.0 g) gave (±)-3-(3-phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an oxalate salt (0.198 g) crystallizing from CHCl₃ -ether, m.p.74°-83° C. (Compound 153).

EXAMPLE 151(±)-3-(4,4,4-trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 13, compound 12 (1.15 g) and bromo-4,4,4-trifluorobutane (1.81g) gave(±)-3-(4,4,4-trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas a HCl salt (1.43 g) crystallizing from CHCl₃ -ether, m.p. 128°-130°C. (Compound 154).

EXAMPLE 152(±)-3-(3-[3-pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 13, compound 12 (1.15 g) and bromo-3-(3-pyridyl)propane (1.42g) gave(±)-3-(3-[3-pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas a HCl salt (0.92 g) crystallizing from CHCl₃ -ether-EtOAc, m.p.202°-204° C. (Compound 155).

EXAMPLE 153(±)-endo-3-(2-Phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used in the preparation ofcompound 72, compound 48 (1.15 g) and bromo-2-phenoxyethane (3.8 g) gave(±)-endo-3-(2-phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazoleas a HCl salt (0.11 g) crystallizing from CHCl₃ -ether-EtOAc, m.p.144°-146° C. (Compound 156).

Alternate Procedure for the Preparation of(±)-exo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate(±)-exo-methyl-2-azabicyclo[2.2.2]oct-5-en-7-one-2-carboxylate

Postassium hydroxide (39.9 g/712 mmol) was added to a solution of methyl7-acetoxy-7-cyano-2-azabicyclo[2.2.2]oct-5-ene-2-carboxylate (J. Org.Chem. 1989, 54, 2893)(35.6 g/142 mmol), ethanol (450 mL), and water (90mL). Stirred at room temperature for 2 hours. Removed the ethanol byevaporation then extracted the aqueous residue with ethyl acetate. Theorganic extracts were dried over magnesium sulfate then evaporated.Purified by preprative HPLC over silica gel eluting with 10 to 100%ethyl acetate in hexanes to yield (+)-exo-methyl2-azabicyclo[2.2.2]oct-5-en-7-one-2-carboxylate (9.2 g/50.8 mmol).

(±)-exo-Methyl-2-azabicyclo[2.2.2]oct-6-one-2-carboxylate

A sample of (±)-exo-Methyl2-azabicyclo[2.2.2]oct-5-en-7-one-2-carboxylate (9.2 g/50.8 mmol) washydrogenated with 5% palladium on carbon (0.5 g) in methanol (150mL) at35 PSIG and room temperature for 1 hour. Filtered off the catalyst andevaporated the filtrate to yield(±)-exo-methyl-2-azabicyclo[2.2.2]oct-6-one-2-carboxylate (9 g).

(±)-exo-Methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

Sodium borohydride (1.4 g/36.1 mmol) was added to a mixture of(±)-exo-methyl-2-azabicyclo[2.2.2]oct-6-one-2-carboxylate (6 g/32.8mmol) and cerium trichloride heptahydrate (13.4 g/36.1 mmol) in methanol(55mL) at 0° C. Stirred at room temperature overnight. The reaction wasevaporated, the residue was taken up in water then extracted with ethylacetate. The organic extracts were dried over magnesium sulfate thenevaporated. The residue was purified by flash chromatagraphy over silicagel eluting with 25% ethyl acetate in hexanes to yield(±)-exo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate (3.6g/19.5 mmol).

(±)-endo-Methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate

Separation of(±)-exo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate and(±)-endo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate,Compound 62, was achieved by hplc over silica gel eluting with a 10% to80% EtOAc-hexane gradient.

EXAMPLE 154(±)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Sodium hydride (19.5 mmol) was added to a solution of(±)-exo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylate (3.6g/19.5 mmol) in tetrahydrofuran (200 mL) at room temperature. Thereaction was stirred for 1 hour whereupon3-chloro-4-propylthio-1,2,5-thiadiazole (3.8 g/19.5 mmol) intetrahydrofuran (50 mL) was added to the reaction and stirred for 16hours at room temperature. The reaction was poured into water andextracted with ethyl acetate. The organic extracts were dried overmagnesium sulfate then evaporated. The residue was purified bypreprative HPLC over silica gel eluting with 5 to 50% ethyl acetate inhexanes to yield [exo](±)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(2.1 g/6.1 mmol). (Compound 157).

EXAMPLE 155(±)-exo-3-Propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

A solution of Oxone® (7.6 g/12.4 mmol) in water(30 mL) was added to asolution of(±)-exo-3-propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(2.1 g/6.1 mmol), water (10 mL), and tetrahydrofuran (20 mL). Stirred atroom temperature for 16 hours. The reaction was extracted with diethylether (3×50 mL). The organic extracts were washed with water, saturatedaqueous sodium bicarbonate, water, dried over magnesium sulfate, thenevaporated to yield(±)-exo-3-propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(2.4 g). (Compound 158).

EXAMPLE 156 (±)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Sodium hydride (4.1 mmol) was added to a solution of4,4,4-trifluorobutanol in tetrahydrofuran (35 mL) at room temperature.Stirred for 2 hours where upon(±)-exo-3-propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(1.0 g/2.7 mmol) in tetrahydrofuran (5 mL) was added to the reaction.The reaction was refluxed for 16 hours. The reaction was poured intobrine then extracted with ethyl acetate (3×75 mL). The organic extractswere dried over magnesium sulfate to yield(±)-exo-3-(4,4,4-trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(1.0 g/2.5 mmol). (Compound 159).

EXAMPLE 157(±)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Trimethylsilyl iodide (0.4 mL/3.0 mmol) was added to a solution of(±)-exo-3-(4,4,4-trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(1.0 g/2.5 mmol) and dichloromethane (30 mL). The reaction was refluxedfor 16 hours then poured into methanol (25 mL), stirred at roomtemperature for 15 minutes, then evaporated. The residue was Purified byradial chromatagraphy on silica gel eluting with 2% ehtanol/10%triethylamine in ethyl acetate to yield(±)-exo-3-(4,4,4-trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazolewhich was isolated as the oxalate salt to yield 251 mg (mp=115°-120°C.). (Compound 160).

EXAMPLE 158(±)-exo-3-(Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Substantially the same procedure used to prepare Compound 160 withsubstition of hexanol for 4,4,4-trifluorobutanol gave(±)-exo-3-(hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazoleoxalate (mp=128°-30° C.). (Compound 161).

EXAMPLE 159(±)-endo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

From (±)-endo-methyl-6-hydroxy-2-azabicyclo[2.2.2]octane-2-carboxylatewas obtained(±)-endo-3-(4,4,4-trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole.Using substantially the same procedure used to synthesize Compound 160.The compound was isolated as the oxalate salt (mp=151°-153° C.).(Compound 162).

EXAMPLE 160(±)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Sodium sulfide nonahydrate (1 g/4.1 mmol) was added to(±)-exo-3-propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(1.3 g/3.5 mmol) in dimethylformamide (25 mL) at 100° C. Stirred for 2hours whereupon 2-bromoethyl 4-fluorophenyl ether (0.9 g/4.2 mmol) indimethylformamide (5 mL) was added to the reaction. Stirred for 1 hourat 100° C. then 16 hours at room temperature. The reaction was pouredinto brine then extracted with ethyl acetate (3×150 mL). The organicextracts were combined and dried over magnesium sulfate then evaporated.The residue was purified by radial chromatagraphy over silica geleluting with 30% ethyl acetate in hexanes to yield(±)-exo-3-(2-[fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(0.9 g/2.1 mmol). (Compound 163).

EXAMPLE 161(±)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole

Trimethylsilyl iodide (0.4 mL/2.5 mmol) was added to a solution of(±)-exo-3-(2-[fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole(0.9 g/2.1 mmol) and dichloromethane (50 mL). The reaction was refluxedfor 16 hours then poured into methanol (25 mL), stirred at roomtemperature for 15 minutes, then evaporated. The residue was purified byradial chromatagraphy on silica gel eluting with 2% ehtanol/10%triethylamine in ethyl acetate to yield(±)-exo-3-(2-[fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazolewhich was isolated as the oxalate salt to yield 222 mg (mp=145°-149°C.). (Compound 164).

EXAMPLE 162 (±)- endo-3-Propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A sample of (±)-endo-1-Azabicyclo[3.2.1]octan-6-ol (5.1 g, 40 mmoles)was added to a solution of potassium t-butoxide (5.4 g, 48 mmoles) in120 ml THF and cooled in an ice bath. Compound 37 (8.0 g, 41 mmoles wasadded and the reaction stirred for 3 hr at room temperature. Ethylacetate was added, the organic layer washed with water, dried oversodium sulfate and condensed to yield 10.0 g of crude product. HPLCpurification eluting with 5% ethanol/chloroform with 0.5% ammoniumhydroxide yielded 8 g of(±)-endo-3-propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazoleas an oil, 71%. (Compound 165).

EXAMPLE 163(±)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of(±)-endo-3-propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole(5.7 g) in 1N HCl (24 mL) was cooled in ice-water and Oxone (36.8 g) inH₂ O (75 mL) was added dropwise over 5 min. Cooling was removed andafter 5 h, excess oxidant was destroyed with NaHSO₃. The reaction waspoured into ice and the pH adjusted to 12. The mixture was extractedwith EtOAc, the extracts washed with water, the solvent dried, and thesolvent evaporated to give analytically pure(±)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazoleas an oil (4.6 g). (Compound 166).

EXAMPLE 164(±)-endo-3-(4,4,4-Trifluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

A solution of 4,4,4-trifluorobutanol (0.32 g) in THF (15 mL) was cooledin ice-water and treated with potassium tert-butoxide (0.4 g). Asolution of Compound 166 (0.4 g) in THF (10 mL) was added dropwise tothe reaction and the mixture stirred 1 h. The reaction was diluted withcold water, the pH adjusted to 12, and the mixture extracted with EtOAc.The extracts were dried and the solvent evaporated. The residue wastreated with dry HCl in ether and the resulting crystals collected,washed with ether, and dried to give a white solid (0.16 g), m.p.155°-156° C. (Compound 167).

The following compounds were obtained by substantially the sameprocedure substituting the appropriate alcohol for the4,4,4-trifluorobutanol.

EXAMPLE 165(±)-endo-3-(2-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-5-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-butynol as the HCl salt in 89% yield,m.p. 200°-201. (Compound 168).

EXAMPLE 166(±)-endo-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and trans-2-butenol as the HCl salt in 54%yield, m.p. 160°-161° C. (Compound 169).

EXAMPLE 167(±)-endo-3-(2-Methylthioethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-methylthioethanol as the HCl salt in85% yield, m.p. 169°-170° C. (Compound 170).

EXAMPLE 168(±)-endo-3-(2-(4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(4-methyl-1,3-thiazol-5-yl)ethanol asthe HCl salt in 73% yield, m.p. 171°-172° C. (Compound 171).

EXAMPLE 169(±)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-methylthiobenzyl alcohol as the HClsalt in 28% yield, m.p. 155°-156° C. (Compound 172).

EXAMPLE 170(±)-endo-3-(2-Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-thiophenemethanol as the HCl salt in29% yield, m.p. 134°-135° C. (Compound 173).

EXAMPLE 171(±)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-cyclohexenol as the HCl salt in 55%yield, m.p. 179°-180° C. (Compound 174).

EXAMPLE 172(±)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-pentynol as the HCl salt in 40% yield,m.p. 118°-119° C. (Compound 175).

EXAMPLE 173(±)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-hexynol as the HCl salt in 27% yield,m.p. 134°-135° C. (Compound 176).

EXAMPLE 174(±)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-chloropropanol as the HCl salt in 48%yield, m.p. 131°-132° C. (Compound 177).

EXAMPLE 175(±)-endo-3-[2-(2-Napthyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(2-napthalyl)ethanol as the HCl salt in34% yield, m.p. 134°-139° C. (Compound 178).

EXAMPLE 176(±)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-methyl-3-pentenol as the HCl salt in98% yield, m.p. 113°-114° C. (Compound 180).

EXAMPLE 177(±)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and cis-2-butenol as the HCl salt in 37%yield, m.p. 151°-152° C. (Compound 181).

EXAMPLE 178 (±)-endo-3-(cyclopropylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and cyclopropylmethanol as the HCl salt in50% yield, m.p. 165°-166° C. (Compound 182).

EXAMPLE 179(±)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-methoxyethanol as the HCl salt in 25%yield, m.p. 123°-124° C. (Compound 183).

EXAMPLE 180(±)-endo-3-(3-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-butenol as the HCl salt in 20% yield,m.p. 168°-169° C. (Compound 184).

EXAMPLE 181(±)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-cyclopropylethanol as the HCl salt in76% yield, m.p. 152°-153° C. (Compound 185).

EXAMPLE 182(±)-endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-butynol as the HCl salt in 65% yield,m.p. 198°-199° C. (Compound 186).

EXAMPLE 183(±)-endo-3-(4,4,4,3,3,2,2-Heptafluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4,4,4,3,3,2,2-heptafluorobutanol as theHCl salt in 23% yield, m.p. 192°-193° C. (Compound 187).

EXAMPLE 184(±)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(3-trifluoromethylphenyl)ethanol as theHCl salt in 38% yield, m.p. 118°-120° C. (Compound 188).

EXAMPLE 185(±)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiozole

Obtained from Compound 166 and 2-(2-thienyl)ethanol as the HCl salt in63% yield, m.p. 119°-120° C. (Compound 189).

EXAMPLE 186(±)-endo-3-(3,3,3,2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3,3,3,2,2-pentafluoropropanol as the HClsalt in 77% yield, m.p. 208°-209° C. (Compound 190).

EXAMPLE 187(±)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-phenoxyethanol as the HCl salt in 80%yield, m.p. 165°-166° C. (Compound 191).

EXAMPLE 188(±)-endo-3-(4-n-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-n-butylbenzyl alcohol as the HCl saltin 18% yield, m.p. 168°-169° C. (Compound 192).

EXAMPLE 189(±)-endo-3-[3-(4-Methoxyphenyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-(4-methoxyphenyl)propanol as the HClsalt in 54% yield, m.p. 161°-162° C. (Compound 193).

EXAMPLE 190 (±)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-fluorobenzyl alcohol as the HCl salt in71% yield, m.p. 163°-164° C. (Compound 194).

EXAMPLE 191(±)-endo-3-(2,4-Difluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2,4-difluorobenzyl alcohol as the HClsalt in 17% yield, m.p. 168°-169° C. (Compound 195).

EXAMPLE 192(±)-endo-3-[4-(Trifluoromethoxy)benzyloxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-trifluoromethoxybenzyl alcohol as theHCl salt in 8% yield, m.p. 185°-186° C. (Compound 196).

EXAMPLE 193(±)-endo-3-(4-Fluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-fluorobutanol as the HCl salt in 56%yield, m.p. 142°-143° C. (Compound 197).

EXAMPLE 194(±)-endo-3-(4-tert-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-tert-butylbenzyl alcohol as the HClsalt in 40% yield, m.p. 192°-194° C. (Compound 198).

EXAMPLE 195(±)-endo-3-(1-cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and (±)-1-cyclopropylethanol as the HCl saltin 39% yield, m.p. 171°-172° C. (Compound 199).

EXAMPLE 196(±)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-cyclohexylethanol as the HCl salt in15% yield, m.p. 139°-141° C. (Compound 200).

EXAMPLE 197(±)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-methyl-2-butenol as the HCl salt in 60%yield, m.p. 149°-150° C. (Compound 201).

EXAMPLE 198(±)-endo-3-(4-Cyclohexylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-cyclohexylbutanol in as the HCl salt 9%yield, m.p. 130°-132° C. (Compound 202).

EXAMPLE 199(±)-endo-3-(3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and (±)-3-butyn-2-ol in 58% yield as the HClsalt, m.p. 179°-180° C. (Compound 203).

EXAMPLE 200(±)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-methyl-3-phenylbutanol as the HCl saltin 34% yield, m.p. 145°-147° C. (Compound 204).

EXAMPLE 201(±)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-fluoropropanol as the HCl salt in 72%yield, m.p. 147°-148° C. (Compound 205).

EXAMPLE 202(±)-endo-3-[3-(2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-(2-thienyl)propanol in 75% yield, m.p.140°-142° C. (Compound 206).

EXAMPLE 203(±)-3-(2-[4-Fluorophenoxy]ethythio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using substantially the same procedure used for the preparation ofcompound 44, compound 12 (1.15 g) and 1-bromo-(4-fluorophenoxy)ethane(3.65 9) gave(±)-3-(2-[4-fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt (1.55 g) crystallizing from ether-EtOAc-CHCl₃, m.p.160°-161° C. (Compound 207).

EXAMPLE 204(±)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of 3-(2-methylthioethyl)-4-hydroxy-1,2,5-thiadiazole (0.45 g)and triphenylphosphine (0.7 g) was cooled in ice-water asdiethyldiazodicarboxylate (0.4 mL) was added dropwise. After addition,(±)-1-azabicyclo[2.2.2]octan-3-ol (0.33 g) was added, cooling removed,and reaction stirred for 1 hour. The solvent was evaporated, residuesuspended in water, the mixture acidified and washed with ether. Theaqueous solution was made basic and extracted with EtOAc. The extractswere dried, the solvent evaporated, the residue purified by radialchromotography eluting with 10%-EtOH-1%-NH₄ OH-CHCl₃, and the productconverted to a HCl salt. Recrystallization from acetone gave 0.6 g whitecrystals, m.p. 177°-178° C. (Compound 208).

The following compounds were synthesized in substantially the samemanner as Compound 208.

EXAMPLE 205 (±)-3-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A sample of 3-Hydroxy-1,2,5-thiadiazole (0.28 g), triphenylphospine (0.7g), diethyldiazodicarboxylate (0.4 mL), and(±)-1-azabicyclo[2.2.2]octan-3-ol (0.33 g) gave the hydrochloride saltof (±)-3-(1-azabicyclo[2.2.2 ]octyl-3-oxy)-1,2,5-thiadiazole, m.p. 240°C. dec. (0.36 g). (Compound 209).

EXAMPLE 206(±)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A sample of 3-Hexyl-4-Hydroxy-1,2,5-thiadiazole (0.93 g),triphenylphospine (1.31 g), diethyldiazodicarboxylate (0.8 mL), and(±)-1-azabicyclo[2.2.2]octan-3-ol (0.64 g) gave the hydrochloride saltof (±)-3-hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,m.p. 163°-164° C. dec. (1.11 g). (Compound 210).

EXAMPLE 207 3-Butylthio-4-hydroxy-1,2,5-thiadiazole

A solution of Compound 1 (20.9 g), DMSO (20 mL) and 2N NaOH (205 mL) washeaded to reflux overnight. The solution was cooled to 15° C. andconcentrated HCl was added until the pH was 1. The solid was collected,washed with water, and dried to give a solid (17.68 g).Recrystallization from heptane gave white crystals, m.p. 72°-72.5° C.(Compound 211).

EXAMPLE 208(±)-3-(2-[3-{1,2,5-Thiadiazoyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

A solution of triphenylphosphine (0.35 g) and3-hydroxy-1,2,5-thiadiazole (0.14 g) in THF (15 mL) was cooled inice-water. Diethyl diazodicarboxylate (0.21 g) was added dropwisefollowed by(+)-3-(2-hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(0.35 g). Cooling was removed, reaction was stirred 1 h, and the solventwas evaporated. The residue was suspended in cold water, acidified, andextracted with ether. The aqueous fraction was made basic and extractedwith EtOAc. The extracts were washed with brine, dried, the solventevaporated, and the residue purified by radial chromatography elutingwith 10%-EtOH-1% NH₄ OH-CHCl₃ to give a clear oil. The HCl saltcrystallized from acetone as a white powder (0.34 g), m.p. 178°-179° C.(Compound 212).

EXAMPLE 209 (±)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole

A solution of triphenylphosphine (0.7 g) and 317260 (0.5 g) in THF (20mL) was cooled in ice-water. Diethyl diazodicarboxylate (0.4 mL) wasadded dropwise followed by addition of(+)endo-3-hydroxy-1-azabicyclo[2.2.1]heptane (0.29 g). Cooling wasremoved and after 1 h the solvent was evaporated. The residue wassuspended in cold water, acidified, and extracted with ether. Theaqueous fraction was made basic and extracted with EtOAc. The extractswere dried, the solvent evaporated, and the residue purified by radialchromatography eluting with 5%-EtOH-0.5% NH₄ OH-CHCl₃ to give a clearoil. The HCl salt crystallized from EtOAc as white crystals (0.44 g),m.p. 147°-148° C. (Compound 213).

EXAMPLE 210 (±)-endo-3-[2-(4-Chlorophenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(4-chlorophenyl)ethanol in 50% yield,HCl salt m.p. 136°-138° C. (Compound 214).

EXAMPLE 211(±)-endo-3-[2-(4-Fluorophenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxo)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(4-fluorophenyl)ethanol in 61% yield,HCl salt m.p. 135°-136° C. (Compound 215).

EXAMPLE 212(+)-endo-3-[2-(3-Methylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(3-methylphenyl)ethanol in 57% yield,HCl salt m.p. 114°-115° C. (Compound 216).

EXAMPLE 213(±)-endo-3-(2-Phenylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy-1,2,5-thiadiazole

Obtained from Compound 166 and 2-phenylethanol in 70% yield, HCl saltm.p. 135°-136° C. (Compound 217).

EXAMPLE 214(±)-endo-3-[2-(3-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-(3-thienyl)ethanol in 62% yield, HClsalt m.p. 142°-144° C. (Compound 218).

EXAMPLE 215(±)-endo-3-Benzyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and benzyl alcohol in 71% yield, HCl saltm.p. 180°-181° C. (Compound 219).

EXAMPLE 216(±)-endo-3-(4-Trifluoromethylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 4-trifluoromethylbenzyl alcohol in 76%yield, maleate salt m.p. 174°-175° C. (Compound 220).

EXAMPLE 217 (5S, 6S)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5S, 6S)-Compound 166 and 4-fluorobenzyl alcohol in 33%yield, HCl salt m.p. 181°-182° C. (Compound 221).

EXAMPLE 218 (5R, 6R)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5R, 6R)-Compound 166 and 4-fluorobenzyl alcohol in 68%yield, maleate salt m.p. 106°-107° C. (Compound 222).

EXAMPLE 219 (5S, 6S)- endo-3-(4-Trifluoromethoxybenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5S, 6S)-Compound 166 and 4-trifluoromethoxybenzyl alcoholin 52% yield, HCl salt m.p. 138°-140° C. (Compound 223).

EXAMPLE 220 (5R,6R)-endo-3-(4-Trifluoromethoxybenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5R, 6R)-Compound 166 and 4-trifluoromethoxybenzyl alcoholin 71% yield, maleate salt m.p. 114°-115° C. (Compound 224).

EXAMPLE 221 (5R,6R)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5R,6R)-Compound 166 and 2-cyclopropylethanol in 84%yield, maleate salt m.p. 111°-112° C. (Compound 225).

EXAMPLE 222 (5S,6S)-endo-3-(2-cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5S, 6S)-Compound 166 and 2-cyclopropylethanol in 78%yield, maleate salt m.p. 109°-110° C. (Compound 226).

EXAMPLE 223 (5R,6R)-endo-3-(3-Methyl-2-butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from (5R,6R)-Compound 166 and 3-methyl-2-butenol in 81% yield,maleate salt m.p. 141°-142° C. (Compound 227).

EXAMPLE 224(±)-endo-3-(2-Cyclopropylideneethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 2-cyclopropylideneethanol in 67% yield,maleate salt m.p. 100°-101° C. (Compound 228).

EXAMPLE 225(±)-endo-3-(3-Cyclopropylpropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 3-cyclopropylpropanol in 62% yield,maleate salt m.p. 114°-115° C. (Compound 229).

EXAMPLE 226(±)-endo-3-(1-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole

Obtained from Compound 166 and 1-cyclopropylethanol in 78% yield,maleate salt m.p. 161°-162° C. (Compound 230).

EXAMPLE 227 (±)exo-3-(1-Azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole

Prepared in the same manner as Compound 131.(±)Exo-3-(1-azabicyclo[2.2.1]heptyl-3 -oxy)-1,2,5-thiadiazole wasobtained from 3 -hydroxy-1,2,5 -thiadiazole (0.14 g), triphenylphosphine(0.35 g), diethyldiazodicarboxylate (0.21 mL) and(±)-endo-1-azabicyclo[2.2.1]heptane-3-ol (0.15 g) as a hydrochloridesalt (0.096 g), m.p. 223° C., dec. (Compound 231).

EXAMPLE 228(±)-3-(3-[3-Trifluoromethyl-4-Chlorophenyl]propoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5 -thiadiazole

Using the same procedure used in the preparation of Compound 103,(3-trifluoromethyl-4-chlorophenyl)propanol and Compound 102 gave afterchromatography(±)-3-(3-[3-trifluoromethyl-4-chlorophenyl]propoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt, m.p. 144°-146° C. (Compound 232).

EXAMPLE 229(±)-3-(3-Phenylpropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole

Using the same procedure used in the preparation of Compound 103,3-phenylpropanol and Compound 102 gave after chromatography(±)-3-(3-phenylpropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt, m.p. 194°-196° C. (Compound 233).

EXAMPLE 230(R)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]oxy)-1,2,5-thiadiazole

Using the same procedure used in the preparation Compound 114,2-cyclopropylethanol and Compound 102 that had been prepared from(R)-1-azabicyclo[2.2.2]octan-3-ol gave afterchromatography,(R)-3-(2-cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazoleas an HCl salt that crystallized from acetone, m.p. 189°-190° C.(Compound 234).

EXAMPLE 231 3-Ethoxy-4-hydroxy-1,2,5-thiadiazole

A mixture of Compound 93 (8.2 g), 2N NaOH (100 mL), and DMSO (10 mL) washeated to reflux over night. The reaction was cooled and extracted withether. The aqueous fraction was acidified with conc. HCl and cooled 30min in ice-water. The solid was collected from the resulting mixture byfiltration and washed with a small amount of cold water to give whitecrystals (4.4 g). Recrystallization from heptane gave white flakes, m.p.104.5°-105.5° C. (Compound 235).

EXAMPLE 232 3-Propylthio-4 -hydroxy-1,2,5-thiadiazole

A mixture of 3-chloro-4-propylthio-1,2,5-thiadiazole (Compound 37) (10g), 2N NaOH (100 mL), and DMSO (10 mL) was heated to reflux for 24 h.The solution was cooled and extracted with ether. The aqueous fractionwas acidified with conc. HCl and cooled in ice-water for 3 h. Theresulting solid was collected, washed with a small amount of cold waterto give a white solid (8.15 g). Recrystallization from heptane gavewhite crystals, m.p. 84°-85° C. (Compound 236).

We claim:
 1. A compound of formula I, or the quaternized form thereof:##STR19## wherein W is oxygen or sulphur;R is hydrogen, amino, halogen,NHR⁶, NR⁶ R⁷, R⁴, --OR⁴, --SR⁴, --SOR⁴, --SO₂ R⁴, C₃₋₁₀ -cycloalkyl,C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀ -cycloalkyl or --Z--C₄₋₁₂-(cycloalkylalkyl); or R is phenyl or benzyloxycarbonyl, each of whichis optionally substituted with one or more substituents independentlyselected from halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃, --CF₃,--CONH₂ and --CSNH₂ ; or R is --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y, --SR⁵ ZY,--O--R⁵ --Z--R⁴ or --S--R⁵ --Z--R⁴ ; Z is oxygen or sulphur; R⁴ is C₁₋₁₅-alkyl, C₂₋₁₅ -alkenyl or C₂₋₁₅ -alkynyl, each of which is optionallysubstituted with one or more substituents independently selected fromhalogen, --CF₃, --CN, Y, phenyl and phenoxy, wherein phenyl or phenoxyis optionally substituted with one or more substituents independentlyselected from halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy, --OCF₃, --CF₃,--CONH₂ and --CSNH₂ ; R⁵ is C₁₋₁₅ -alkylene, C₂₋₁₅ -alkenylene, andC₂₋₁₅ -alkynylene; Y is a 5 or 6 membered heterocyclic group; G isselected from one of the following azacyclic or azabicyclic ringsystems: ##STR20## or G is C₃ -C₈ cycloalkyl optionally substituted byR¹, R² or --NR⁶ R⁷ ; or G is C₁₋₆ -alkyl optionally substituted by --NR⁶R⁷ ; R⁶ and R⁷ independently are hydrogen or C₁₋₆ -alkyl; or R⁶ and R⁷together form a C₃ -C₅ -alkylene group which together with the nitrogenatom form a 4- to 6-membered ring; R¹ and R² independently are hydrogen,C₁₋₁₅ -alkyl, C₂₋₅ -alkenyl, C₂₋₅ -alkynyl, C₁₋₁₀ -alkoxy, or C₁₋₅-alkyl substituted with one or more substituents independently selectedfrom --OH, --COR^(6'), CH₂ --OH, halogen, --NH₂, carboxy, and phenyl;R^(6') is hydrogen or C₁₋₆ -alkyl; R³ is hydrogen, C₁₋₅ -alkyl, C₂₋₅-alkenyl or C₂₋₅ -alkynyl; m, n, p and r are independently 0, 1 or 2; qis 1 or 2; and ------- is a single or double bond; provided that: 1)when W is oxygen and G is alkyl, R cannot be halogen; and 2) one of m,n, or p must be other than 0; ora pharmaceutically acceptable salt orsolvate thereof.
 2. A compound of claim 1 wherein G is a saturatedazabicyclic group having from 7 to 11 carbon atoms wherein the ringnitrogen atom is separated from W by 2 or 3 ring carbon atoms; R is R⁴,C₃₋₁₀ -cycloalkyl, C₄₋₁₂ -(cycloalkylalkyl), --Z--C₃₋₁₀ -cycloalkyl or--Z--C₄₋₁₂ -(cycloalkylalkyl); orR is phenyl which is substituted with--CN, --OCF₃, --CONH₂ or --CSNH₂ ; or R is --OR⁵ Y, --SR⁵ Y, OR⁵ --Z--Y,--SR⁵ ZY, --O--R⁵ --Z--R⁴ or --S--R⁵ --Z--R⁴ ; or R is benzyloxycarbonyloptionally substituted with halogen, --CN, C₁₋₄ -alkyl, C₁₋₄ -alkoxy,--OCF₃, --CF₃, --CONH₂ or --CSNH₂ ; and R⁴ is optionally substitutedC₅₋₁₅ -alkyl, C₂₋₁₅ -alkenyl or C₂₋₁₅ -alkynyl, or R⁴ is C₁ -C₄ alkylwhich has with one or more --CN, --OCF₃, --CF₃, --CONH₂ or --CSNH₂substituents.
 3. A compound selected from the group consistingof:(±)-3-(2-(5-(2-Thienyl) thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;(±)-3-(2-(2-(5-(2-Thienyl)thienyl)thio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;(±)-3-(2-(5-(2-Thienyl)thienyl)thio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;(±)-3-(3-N-(2-Thiazolidinyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;3-Butylthio-4-hydroxy-1,2,5-thiadiazole;(±)-3-(2-[3-(1,2,5-Thiadiazolyloxy)]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;(±)-trans-3-Butylthio-4-(N-tert-butylcarboxy-4-hydroxy-pyrrolidin-3-oxy)-1,2,5-thiadiazole;(±)-trans-3-Butylthio-4-(4-hydroxy-pyrrolidin-3-oxy)-1,2,5-thiadiazole;(±)-3-(3-[4-Fluorophenyl]propan-3-onethio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;(±)-exo-3-Propythio-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole;(±)-exo-3-Propylsulfonyl-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole;(±)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole;(±)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-methoxycarbonyl-2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(4-Methylthiobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(2-Cyclohexenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-[2-(2-Naphthyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(4-Chloro-α-cyclopropyl-benzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-endo-3-(4-Cyclohexylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole;(±)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole;3-Butylthio-4-hydroxy-1,2,5-thiadiazole; and(±)-3-(2-[3-{1,2,5-Thiadiazolyloxy}]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole.4. A compound of claim 1 wherein G is cycloalkyl optionally substitutedby NR⁶ R⁷.
 5. A compound of claim 1 wherein p is O.
 6. A compound ofclaim 1 wherein p is G is het-1, het-2, or het-3 and m, n and p are 0or
 1. 7. A compound of claim 1 wherein G is het-4, het-5, or het-6 andm, n and p are 0 or
 1. 8. A compound of claim 1 wherein G is het-7 and mand q are 0 or
 1. 9. A compound of claim 1 wherein W is S.
 10. Acompound of claim 9 wherein r is
 0. 11. A compound of claim 1 wherein Wis O.
 12. A compound of claim 11 wherein G is selected from the groupconsisting of het-1, het-2, het-3, het-5, het-6, and het-7.
 13. Acompound of claim 12 wherein G is unsaturated.
 14. A compound of claim 1wherein G is selected from the group consisting of ##STR21##
 15. Acompound according to claim 14 wherein G is ##STR22##
 16. A compoundaccording to claim 1 which is selected from the group consisting of thefollowing:(±)-3-Methoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Ethoxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Propyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Butyloxy-4-(1-azabicyclo[2.2.2]octyl -3-oxy)-1,2,5-thiadiazole,(±)-3-Pentyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Hexyloxy-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Methylpentyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Chloro-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Propylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Butylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(S)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Hexylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3,3-Dimethylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-(2-Thienylthio)ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2,2,3,3,3-Pentafluoropropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-(2-Thienyl)propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Butylthio-4-((1-azabicyclo[2.2.2]octan-3-yl)methoxy)-51,2,5-thiadiazole,(±)-Exo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-Endo-3-pentylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-Endo-3-butyloxy-4-(1-azabicyclo[2.2.1 ]heptyl-3-oxy)-1,2,5-thiadiazole, (±)-Exo-3-butyloxy-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Butyloxy-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole,(±)-3-Butyloxy-4-(1-methyl -3-pyrrolidinyloxy)-1,2,5-thiadiazole,(±)-3-Butylthio-4-(1-methyl-3-piperidyloxy)-1,2,5-thiadiazole,3-Butylthio-4-(1-methyl-4-piperidyloxy)-1,2,5-thiadiazole,(S)-3-Butyloxy-4-(1-methyl-2-pyrrolidinylmethoxy)-1,2,5-thiadiazole,(S)-3-Butyloxy-4-(2-pyrrolidinylmethoxy)-1,2,5-thiadiazole,3-Butyloxy-4-(2-(dimethylamino)ethoxy)-1,2,5-thiadiazole,3-Butylthio-4-(2-(diethylamino)ethoxy)-1,2,5-thiadiazole,3-Butyloxy-4-(2-(trimethylamino)ethoxy)-1,2,5-thiadiazole iodide,3-Butyloxy-4-(2-(dimethylamino)ethylthio)-1,2,5-thiadiazole,(R)-3-Pentylthio-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Methylpentylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Phenylpropylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Cyanobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Fluorobenzylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Phenylethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Phenyloxyethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,Endo-3-butyloxy-4-(N-methyl -8-azabicyclo[3.2.1]octyl-3-oxy)-1,2,5-thiadiazole,(±)-Exo-3-butyloxy-4-(6-(N-methyl-8-azabicyclo[3.2.1]octan-3-onoxy))-1,2,5-thiadiazole,(±)-Exo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-Endo-3-chloro-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-Endo-3-(4-cyanobenzylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,3-Butyloxy-4-(3-azetidinyloxy)-1,2,5-thiadiazole,3-Butylthio-4-(3-azetidinyloxy)-1,2,5-thiadiazole,(±)-Trans-3-butyloxy-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole(±)-3-Butylthio-4-(3-pyrrolidinyloxy)-1,2,5-thiadiazole,(±)-3-(2-(2-Thio-5-trifluoromethylthienyl)ethylthio)-4-(1-azabicyclo[2.2.2]octyl3-oxy)-1,2,5-thiadiazole, (±)3-Butylthio-4-(exo-2-azabicyclo[2.2.2]oct-6-yloxy)-1,2,5-thiadiazole,(±)3-(2,2,3,3,4,4,4-heptafluorobutyloxy)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole,(±)3-(1-butylthio)-4-[endo-6-(1-azabicyclo[3.2.1]octyloxy)]-1,2,5-thiadiazole(±)3-(3-phenylpropylthio)-4-[endo-6-(1-azabicyclo-[3.2.1]octyloxy)]-1,2,5-thiadiazole,(±)3-[3-(4-fluorophenyl)propylthio]-4-[-3-(1-azabicyclo-[2.2.2]octyloxy)]-1,2,5-thiadiazole,(±)3-(3-[4-(trifluoromethyl)phenyl]propylthio)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole;and (±)3-(1-Butylamino)-4-[-3-(1-azabicyclo[2.2.2]octyloxy)]-1,2,5-thiadiazole;ora pharmaceutically acceptable salt thereof.
 17. A compound of claim 1wherein - - - is a double bond.
 18. A compound of claim 1 wherein G isan azacyclic ring system.
 19. A compound of claim 1 wherein G is anazabicyclic ring system having less than 7 or more than 11 ring carbonatoms.
 20. A compound of claim 1 wherein the compound is selected fromthe group consistingof(±)-3-(2-Methylthioethyl)-4-(1-azabicyclo[2-2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Butylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole(±)-3-Propylsulfonyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4,4,4-Trifluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Butynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(Cyclopropylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3- Phenylpropynyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Methoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[2.2.2]octyl -3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Butynoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Cyclopropylethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-5oxy)-1,2,5-thiadiazole,(±)-3-(2-(Methylthio)ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Chloropropoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Fluorobutyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-[4-Chlorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-[2-methoxy-5-pyridyl]propyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(trans-3-Chloro-2-propenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-[4-Fluorophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4-Pentenyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Fluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(Cyclobutylmethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3,3,3,2,2-Pentafluoropropyloxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-[Phenylthio]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-[1-napthyloxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-[4-Bromophenoxy]ethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(2-Hydroxyethoxy)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole(±)-exo-3-Butyloxy-4-(7-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole(±)-3-Butyloxy-4-(3-piperidinyloxy)-1,2,5-thiadiazole,3-Butyloxy-4-(cis-1R-2-aminocyclopentanoxy)-1,2,5-thiadiazole,(±)-endo-3-Hexyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole(5S,6S)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(5R,6R)-endo-3-Butylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-trans-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole,(±)-cis-3-Butylthio-4-(1-azabicyclo[4.3.0]nonyl-5-oxy)-1,2,5-thiadiazole(±)-trans-3-Butylthio-4-(2-dimethylaminocyclopentyloxy)-1,2,5-thiadiazole,3-Butylthio-4-(2-dimethylaminoethoxy)-1,2,5-thiadiazole, (±)-endo-3-Butyloxy-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-3-(4-Phenylbutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Phenyl-2-propenylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-[N-Phenothiazinyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-[4-Fluorophenyl]-3-[4-fluorophenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-Phenyl-3-[4-trifluoromethylphenoxy]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(4,4,4-Trifluorobutylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(3-[3-Pyridyl]propylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Phenoxyethylthio)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-exo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole,(±)-exo-3-(Hexyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4,4,4-Trifluorobutyloxy)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole,(±)-exo-3-(2-[Fluorophenoxy]ethylthio)-4-(2-azabicyclo[2.2.2]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-Propylthio-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-Propylsulfonyl-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4,4,4-Trifluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(trans-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Methylthioethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-(4-Methyl-1,3-thiazol-5-yl)ethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Thienylmethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Pentynyloxy)-4-(1-azabicyclo[3.2.1 ]octyl -6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Hexynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Chloropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4-Methyl-3-pentenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(cis-2-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Methoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Butenyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Butynyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4,4,4,3,3,2,2-Heptafluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-[2-(3-Trifluoromethylphenyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-[2-(2-Thienyl)ethoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3,3,3,2,2,Pentafluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Phenoxyethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4-n-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-[3-(4-Methoxyphenyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4-Fluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2,4-Difluorobenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-[4-(Trifluoromethoxy)benzyloxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4-Fluorobutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(4-tert-Butylbenzyloxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(2-Cyclohexylethoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Butyn-2-oxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Methyl-3-phenylbutoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-(3-Fluoropropoxy)-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-endo-3-[3-(2-Thienyl)propoxy]-4-(1-azabicyclo[3.2.1]octyl-6-oxy)-1,2,5-thiadiazole,(±)-3-(2-[4-Fluorophenoxy]ethylthio)-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-(1-Azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)-3-Hexyl-4-(1-azabicyclo[2.2.2]octyl-3-oxy)-1,2,5-thiadiazole,(±)Exo-3-Butylthio-4-(1-azabicyclo[2.2.1]heptyl-3-oxy)-1,2,5-thiadiazole.21. A compound of claim 1 which is exo.
 22. A compound of claim 1 whichis endo.
 23. A compound of claim 1 wherein G is a 2-aza-2.2.2azabicyclic substituent.
 24. A compound of claim 1 wherein G is a 2.2.1azabicyclic substituent.
 25. A pharmaceutical formulation comprising acompound of claim 1 together with a pharmaceutically acceptable carrieror diluent.
 26. A pharmaceutical formulation of claim 25 wherein theformulation is a dosage unit for oral or parenteral administration. 27.A pharmaceutical formulation according to claim 26, wherein the dosageunit comprises from about 0.1 to about 100 mg of the compound.
 28. Apharmaceutical formulation for treating a disease in the central nervoussystem caused by malfunctioning of the muscarinic cholinergic systemcomprising an effective amount of a compound of claim 1 together with apharmaceutically acceptable carrier or diluent.
 29. A method of treatinga disease in the central nervous system caused by malfunctioning of themuscarinic cholinergic system comprising administering to a subject inneed thereof an effective amount of a compound of claim
 1. 30. A methodfor treating a condition associated with the modulation of a muscariniccholinergic receptor comprising administering to a subject in needthereof an effective amount of a compound of claim
 1. 31. A method forinteracting with a muscarinic cholinergic receptor comprisingadministering an effective amount of a compound of claim 1 to a subjectin need thereof.